Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download FUNDING NEWSLETTER APRIL 2014 NIH NOTICES
Document related concepts
no text concepts found
Transcript
FUNDING NEWSLETTER APRIL 2014 Notice of Intent to Publish a Funding Opportunity Announcement for Centers of Cancer Nanotechnology Excellence (U54) (NOT-CA-14033) Notice of National Cancer Institute (NCI) Participation in PA-14-156 "Extended Development, Hardening and Dissemination of Technologies in Biomedical Computing, Informatics, and Big Data Science (R01)" (NOTCA-14-041) National Cancer Institute "http://grants.nih.gov/grants/guide/notice-files/NOT-CA-14033.html" National Cancer Institute "http://grants.nih.gov/grants/guide/notice-files/NOT-CA-14041.html" Notice of National Cancer Institute's Interest in Supporting Cancer Nanotechnology Research Training Programs (NOT-CA-14-035) Notice of Agency Decision: The Density of the Primary Living Space of Captive Chimpanzees Owned or Supported by the NIH or Used in NIHSupported Research (NOT-OD-14-051) NIH NOTICES National Cancer Institute "http://grants.nih.gov/grants/guide/notice-files/NOT-CA-14035.html" Notice of Expiration of PAR-14-013 "Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R21)" (NOT-CA-14-036) National Cancer Institute "http://grants.nih.gov/grants/guide/notice-files/NOT-CA-14036.html" Notice of Intent to Publish a Funding Opportunity Announcement for Cancer Nanotechnology Research Platforms (U01) (NOT-CA-14-037) National Cancer Institute "http://grants.nih.gov/grants/guide/notice-files/NOT-CA-14037.html" Notice of Intent to Publish a Funding Opportunity Announcement for the Physical SciencesOncology Network (PS-ON): Physical SciencesOncology Projects (PS-OP) (U01) (NOT-CA-14-039) National Cancer Institute "http://grants.nih.gov/grants/guide/notice-files/NOT-CA-14039.html" Notice of National Cancer Institute (NCI) Participation in PA-14-155 "Early Stage Development of Technologies in Biomedical Computing, Informatics, and Big Data Science (R01)" (NOT-CA-14-040) National Cancer Institute "http://grants.nih.gov/grants/guide/notice-files/NOT-CA-14040.html" SCCC Research Administration National Institutes of Health "http://grants.nih.gov/grants/guide/notice-files/NOT-OD-14051.html" NIH Will Open the Research Performance Progress Report (RPPR) for All Type 5 Non-SNAP Progress Reports on April 25, 2014 (NOT-OD-14064) National Institutes of Health "http://grants.nih.gov/grants/guide/notice-files/NOT-OD-14064.html" Notice of Online Data Submission and Access to the National Institutes of Health (NIH) database of Genotypes and Phenotypes (dbGaP) (NOT-OD-14065) National Institutes of Health "http://grants.nih.gov/grants/guide/notice-files/NOT-OD-14065.html" Notice of Reissuance of the Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship Funding Opportunity Announcements (NOT-OD-14-066) National Institutes of Health "http://grants.nih.gov/grants/guide/notice-files/NOT-OD-14066.html" Request for Information: Invitation to Comment on Proposed Guidance Regarding Significant Changes to Ongoing Animal Activities (NOT-OD14-063) National Institutes of Health "http://grants.nih.gov/grants/guide/notice-files/NOT-OD-14063.html" April 2014 Funding Newsletter Page 1 of 49 Adjustments to May 25-28, 2014 Grant Application Due Dates (NOT-OD-14-070) National Institutes of Health "http://grants.nih.gov/grants/guide/notice-files/NOT-OD-14070.html" NIH Extramural Grant Systems Upgrade for Unicode Compatibility Means Memorial Day Weekend Downtime (NOT-OD-14-071) National Institutes of Health "http://grants.nih.gov/grants/guide/notice-files/NOT-OD-14071.html" Request for Information (RFI): Availability of Data and Samples from Randomized Smoking Cessation Trials (NOT-DA-14-005) National Cancer Institute "http://grants.nih.gov/grants/guide/notice-files/NOT-DA-14005.html" Maintaining Confidentiality in NIH Peer Review (NOT-OD-14-073) National Institutes of Health "http://grants.nih.gov/grants/guide/notice-files/NOT-OD-14073.html" APRIL DEADLINES Foundation and Other Sources Association for International Cancer Research (AICR) Research Grants April 25, 2014 Application Due Date: "http://www.aicr.org.uk/applyingforagrant.stm" About AICR awards project grants of between one and three years to support fundamental and translational research into the causes, mechanisms, diagnosis, treatment and prevention of cancer. Period of Support Funds/Direct Costs Program Contact Up to 3 years AICR does not have a formal upper limit for project budgets AICR [email protected] Bladder Cancer Advocacy Network (BCAN) Bladder Cancer Research Innovation Award February 12, 2014 Letter of Intent Due Date: April 23, 2014 Application Due Date: "http://www.bcan.org/research/grants/bladder-cancerresearch-innovation-award/" SCCC Research Administration About The application process is now open for BCAN’s Bladder Cancer Research Innovation Award. BCAN is pleased to announce this award, which will support the work of one investigator with an exceptionally novel and creative project with great potential to produce a breakthrough in the management of bladder cancer. Letters of Intent (LOI) are required and are due by February 12, 2014. Selected applicants will be chosen to submit full proposals. If invited, full proposals are due by April 23, 2014. Period of Support Funds/Direct Costs Program Contact 2 years $300,000 total costs over entire period of support Bladder Cancer Advocacy Network (BCAN) [email protected] Margaret Q. Landenberger Research Foundation Research Grant University of Miami Internal Review Deadline: Application Due Date: February 14, 2014 April 15, 2014 About The Margaret Q. Landenberger Research Foundation (“the Foundation”) is a non-profit private foundation which focuses its support on promising, early stage medical researchers. The ideal candidate is affiliated with an outstanding medical research institution and works under the supervision of experienced mentors. Our goal is to assist these individuals by funding their current research, with the hope of enabling them to acquire more significant funding. We do not restrict our support to any particular disease or medical condition. Since the University of Miami may only submit one proposal, this opportunity is a limited submission competition. The internal application deadline is February 14, 2014. An expert panel will internally review our candidates to determine which application will be submitted for competition by the Margaret Q. Landenberger Research Foundation deadline on April 15, 2014. 2 years Period of Support Funds/Direct Costs $100,000 direct costs per year Karen Del Rio Internal Contact [email protected] Multiple Myeloma Research Foundation Research Fellow Award April 22, 2014 Application Due Date: "http://www.themmrf.org/research-programs/for-academicresearchers/grant-opportunities.html#fellows" About The Multiple Myeloma Research Foundation (MMRF) seeks proposals for the Research Fellow Award Program, an initiative supporting researchers with less than five years experience (post graduate degree) working under the supervision of a research mentor in the multiple myeloma field. The goal of this initiative is to help support young April 2014 Funding Newsletter Page 2 of 49 investigators studying in the field of multiple myeloma while advancing the understanding of myeloma disease biology, treatment and drug resistance. Up to 1 year Period of Support Funds/Direct Costs $75,000 total costs for 1 year Up to 10% indirect costs are allowed Budgetary Notes Program Contact Mariadora Saladino, MPA (203) 229-0464 [email protected] Request for Applications (RFA) Multiple Institutes, including the National Cancer Institute Empirical Research on Ethical Issues Related to Central IRBs and Consent for Research Using Clinical Records and Data (R01) RFA-OD-14-002 April 18, 2014 Application Due Date: "http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-14002.html" About The purpose of this Funding Opportunity Announcement (FOA) is to encourage Research Project Grant (R01) applications to explore two timely issues of significance for policy development relevant to: 1) the principles and characteristics for central Institutional Review Boards (IRBs); and 2) consent and participant preferences for research using clinical records and data. This FOA utilizes the NIH (R01) Research Project Grant award mechanism. Period of Support Funds/Direct Costs Program Contact Up to 3 years Application budgets are not limited but need to reflect the actual needs of the proposed project Clarlisse Caga-Anan (240) 276-6738 [email protected] Multiple Institutes, including the National Cancer Institute Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics & Prognostics (R44) RFA-CA-14-002 April 21, 2014 Application Due Date: "http://grants1.nih.gov/grants/guide/rfa-files/RFA-CA-14002.html" SCCC Research Administration About The National Cancer Institute (NCI) invites applications for Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for projects that were previously funded by NIH SBIR Phase II awards. Projects proposed in response to this FOA must be applicable to one of the following areas: (1) cancer therapeutics; (2) cancer imaging technologies, interventional devices, and in vivo diagnostics; or (3) in vitro and ex vivo cancer diagnostics and prognostics. This FOA will utilize the NIH (R44) Small Business Innovation Research (SBIR) Grant - Phase II only. 3 years Period of Support Funds/Direct Costs $3M total costs per year Program Contact Andrew J. Kurtz (240) 276-5228 [email protected] MAY/JUNE DEADLINES Foundation and Other Sources Florida Department of Health Florida Translational Research Program Awards Deadline: May 29, 2014 "http://www.sanfordburnham.org/technology/centers/cpccg/fl oridatranslationalresearchprogram/Pages/ProgramDescription.aspx" About The purpose of the Florida Translational Research Program (FTRP) is to produce a pipeline of potential new medicines based upon laboratory research discoveries. The Program provides Florida-based scientists with access to experienced professionals and state-of-the-art technological resources for drug discovery to facilitate an interdisciplinary, collaborative approach to the establishment of a pipeline of potential new treatments for today’s most challenging and unmet medical needs. The Program is funded by the state of Florida through the Florida Department of Health and is administered and performed by Sanford-Burnham Medical Research Institute at Lake Nona. The goals of the FTRP are to implement a variety of innovative biochemical and cell-based assays to interrogate biological targets or processes for which there are limited selective and potent small-molecule modulators available; to execute high-throughput screens; and to develop lead compounds suitable for use in vivo. April 2014 Funding Newsletter Page 3 of 49 Period of Support Unspecified Funds/Direct Costs There is no transfer of funds associated with selection of projects, successful applicants will obtain access to resources that can be applied to the discovery and development of innovative chemical tools for use in biological research Program Contact Florida Translational Research Program [email protected] Ovarian Cancer Research Fund, Inc. Program Project Development Grant May 6, 2014 Application Due Date: "http://www.ocrf.org/ovarian-cancer-research/ourgrantees/program-project-development-grant" About The purpose of this program is to provide funds for ovarian cancer research that may involve several investigators within one institution or collaborations between groups in multiple institutions. Period of Support 3 years Funds/Direct Costs Up to $300,000 direct costs per year Budgetary Notes No indirect costs allowed Program Contact Sarah DeFeo (212) 268-1002 [email protected] Elsa U. Pardee Foundation Research Grants Deadline: June 1, 2014 "http://www.pardeefoundation.org/grants.aspx" About The Elsa U Pardee Foundation funds research directed toward identifying new treatments or cures for cancer. The sponsor particularly encourages grant applications for a one year period which will allow establishment of capabilities of new cancer researchers, or new cancer approaches by established cancer researchers. Project relevance to cancer detection, treatment, or cure should be clearly identified. Period of Support Up to 1 year Funds/Direct Costs Unspecified Budgetary Notes Applications requesting more than twenty-five percent overhead are usually not considered Program Contact Elsa U. Pardee Foundation P.O. Box 2767 Midland, MI 48641-2767 (989) 832-3691 [email protected] SCCC Research Administration Department of Defense Breast Cancer Research Program (BCRP) Breakthrough Award Levels 3 and 4 Preliminary Application Due: May 14, 2014 August 15, 2014 Application Due Date: "http://cdmrp.army.mil/funding/pa/14bcrpbreakthrough34_pa .pdf" About The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are: --Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must be significant and move beyond an incremental advancement. Applications must articulate the pathway to making a clinical impact for individuals with, or at risk for, breast cancer, even if clinical impact is not an immediate outcome. --Research Scope: Research proposed under this award mechanism may be small- to large-scale projects, at different stages of idea and research development. Pre-applications are required and must be received by May 14, 2014. The sponsor will invite selected applicants to submit full proposals. If invited, full proposals must be received by August 15, 2014. Period of Support 5 years Funds/Direct Costs Level 3 funding: $2.5M direct costs for the entire period of support; Level 4 funding: $10M direct costs for the entire period of support Program Contact Congressionally Directed Medical Research Program (301) 682-5507 [email protected] L’Oréal USA L’Oréal For Women in Science Fellowship Program May 19, 2014 Application Due Date: "www.lorealusa.com/forwomeninscience" About The L’Oréal USA For Women In Science fellowship program will award five post‐doctoral women scientists in the United States this year with grants of up to $60,000 each. Applicants are welcome from a variety of fields, including the life and physical/material sciences, technology (including computer science), engineering, and mathematics. Period of Support One-time award Funds/Direct Costs Up to $60,000 total costs for onetime award Program Contact Myriam Coneim [email protected] April 2014 Funding Newsletter Page 4 of 49 B*CURED Research Grant June 1, 2014 Application Due Date: "http://bcured.org/for-researchers/" About B*CURED’s primary goal is to fund innovative brain cancer research. Grants are presented annually by B*CURED to Assistant Professors/ Instructors whose research proposals demonstrate the highest chance of generating novel, meaningful data that will ultimately lead to an NIH-funded research program dedicated to a cure for malignant brain tumors. Period of Support One-time award Funds/Direct Costs $50,000 total costs for one-time award Program Contact B*CURED (203) 869-6048 [email protected] NEW Call for Applications: Alex's Lemonade Stand Foundation Bio-Therapeutics Impact Award June 12, 2014 Application Due Date: "http://www.alexslemonade.org/grants/programareas/accelerator-programs" About The Bio-Therapeutics Impact Award accelerates the development of clinical trials for promising biologic approaches to treating childhood cancer. These approaches include, but are not limited to, immunotherapy, gene therapy and small molecules. The award is intended for investigators who are initiating clinical trials or undertaking the pre-clinical work necessary to move into the IND (investigational new drug) phase. Period of Support 3 years Funds/Direct Costs Up to $1.5M total costs for entire period of support Program Contact Jenny Filer (610) 649-3034 [email protected] Patient-Centered Outcomes Research Institute (PCORI) Improving Methods for Conducting PatientCentered Outcomes Research March 7, 2014 Letter of Intent Due Date: May 6, 2014 Application Due Date: "http://www.pcori.org/funding-opportunities/fundingannouncements/improving-methods-for-conducting-patientcentered-outcomes-research-spring-2014-cycle/" SCCC Research Administration About In this PCORI Funding Announcement (PFA), the Improving Methods for Conducting Patient - Centered Outcomes Research program seeks projects to address gaps in methodological research relevant to conducting PCOR. Results of these projects will inform future iterations of The PCORI Methodology Report. The improvement of existing methods will benefit all stakeholders, including researchers planning investigations, policy makers weighing the value of healthcare interventions; and patients, clinicians, and caregivers facing healthcare decisions. Letters of intent are required and due by March 7, 2014. Selected applicants will be chosen to submit full proposals. If invited, full proposals are due by May 6, 2014. Period of Support Up to 3 years Funds/Direct Costs Up to $750,000 direct costs per year Program Contact PCORI [email protected] Patient-Centered Outcomes Research Institute (PCORI) Communication and Dissemination Research Program March 10, 2014 Letter of Intent Due Date: May 6, 2014 Application Due Date: "http://www.pcori.org/funding-opportunities/fundingannouncements/communication-and-disseminationresearch-spring-2014-cycle/" About PCORI invites applications for projects that address critical knowledge gaps in the communication and dissemination process, both the communication and dissemination of research results to patients, their caregivers, and clinicians, as well as the communication between patients, caregivers, and clinicians in the service of enabling patients and caregivers to make the best possible decisions in choosing among available options for care and treatment. Letters of intent are required and due by March 10, 2014. Selected applicants will be chosen to submit full proposals. If invited, full proposals are due by May 6, 2014. Period of Support 3 years Funds/Direct Costs $500,000 direct costs per year Program Contact PCORI (202) 627-1884 [email protected] Patient-Centered Outcomes Research Institute (PCORI) Effectiveness of Transitional Care March 10, 2014 Letter of Intent Due Date: May 6, 2014 Application Due Date: "http://www.pcori.org/funding-opportunities/fundingannouncements/the-effectiveness-of-transitional-care/" April 2014 Funding Newsletter Page 5 of 49 About PCORI is soliciting applications for research to determine which transitional care service clusters are most effective in improving patient-centered outcomes while optimizing readmission rates in different at-risk subpopulations and in different healthcare contexts (e.g., fee-for-service, capitation, new payment models, medical homes, and integrated delivery systems). Letters of intent are required and due by March 10, 2014. Selected applicants will be chosen to submit full proposals. If invited, full proposals due by May 6, 2014. Period of Support 3 years Funds/Direct Costs $15M total costs over entire period of support Program Contact PCORI [email protected] Patient-Centered Outcomes Research Institute (PCORI) Improving Healthcare Systems March 10, 2014 Letter of Intent Due Date: May 6, 2014 Application Due Date: "http://www.pcori.org/funding-opportunities/fundingannouncements/improving-healthcare-systems-spring2014-cycle/" Pediatric Cancer Research Foundation (PCRF) Designated Grant Program May 1, 2014 Application Due Date: "http://www.pcrfkids.org/site/c.bjJULdNRJkL4H/b.8483009/k.95B0/Grant_Le vels.htm" About Funds projects in communities or regions local to the specific donor or fundraising activity. Outside contributing organizations, fundraisers and donors work with the Foundation to identify a specific project, focus on a specific disease type, facility or awareness program. Period of Support 1 year, can be renewed annually Funds/Direct Costs Up to $50,000 direct costs per year Budgetary Notes Indirect costs are not allowed Program Contact Jeri Wilson [email protected] Pediatric Cancer Research Foundation (PCRF) High Impact Grant May 1, 2014 Application Due Date: "http://www.pcrfkids.org/site/c.bjJULdNRJkL4H/b.8483009/k.95B0/Grant_Le vels.htm" About The Improving Healthcare Systems (IHS) program within the Patient-Centered Outcomes Research Institute (PCORI) invites applications for research comparing the effectiveness of innovative features of health cares systems e.g., innovative technologies, incentives and/or personnel deployments intended to optimize the quality, outcomes, and/or efficiency of care for the patients they serve. Healthcare systems are composed of many components and processes, including private and public health insurance plans; physician groups; hospitals, nursing homes, and assisted living facilities; academic medical centers; integrated delivery systems; community-based and safety-net clinics; federal, state, and municipal providers; and other entities organized to deliver, improve, arrange, purchase, or coordinate health care services. PCORI seeks studies that will provide valuable knowledge to patients, their caregivers, and clinicians, as well as to healthcare leaders, regarding which features of systems lead to improved outcomes that are important to patients and their families. Letters of intent are required and due by March 10, 2014. Selected applicants will be invited to submit full proposals. If invited, full proposals are due by May 6, 2014. About These grants are designed to fill the critical need for startup funds for young researchers to pursue exciting research ideas. Because grant funds are scarce, it is difficult for those early in their careers to compete with more established researchers. These grants keep new researchers focused on childhood cancer. These grants are for scientists focused on innovative research offering the greatest potential to design treatments and improve outcomes for children with difficult-to-treat cancers. These grants encourage and cultivate the best and brightest researchers of the future and may lead to long term commitments to research projects. Period of Support Up to 5 years Funds/Direct Costs Up to $5M direct costs per year Program Contact PCORI [email protected] May 1, 2014 Application Due Date: "http://www.pcrfkids.org/site/c.bjJULdNRJkL4H/b.8483009/k.95B0/Grant_Le vels.htm" SCCC Research Administration Period of Support 1 year, can be renewed annually Funds/Direct Costs Up tp $75,000 direct costs per year Budgetary Notes Indirect costs are not allowed Program Contact Jeri Wilson [email protected] Pediatric Cancer Research Foundation (PCRF) Translation Research Grant About This grant primarily funds new research protocols and therapies that hold promise for improved outcomes and accelerates cures from the laboratory bench to the bedside of children and teens with high-risk cancers. This Grant will be given to a program that involves open, multi-institutional cancer clinical trials, or consortia, and implements new April 2014 Funding Newsletter Page 6 of 49 approaches to therapy. Period of Support Multiple years Funds/Direct Costs Up to $250,000 direct costs per year Budgetary Notes Indirect costs are not allowed Program Contact Jeri Wilson [email protected] Society of Interventional Radiology Foundation Harvey L. Neiman Health Policy Institute Cost-Effectiveness and Quality Outcomes Research Grant June 1, 2014 Application Due Date: "http://www.sirfoundation.org/grants-awards/" About The Cost-Effectiveness and Quality Outcomes Research Grant is designed to fund research evaluating the cost, costeffectiveness, and quality and outcomes of interventional radiology interventions and treatment approaches in comparison to other established and emerging treatments. These grants should emphasize observational studies and secondary data analyses evaluating the use of image guided minimally invasive therapies in real-world settings. The research from these studies would provide health care providers, patients, health insurers, and policy makers with additional information upon which to base decisions concerning the incorporation of these procedures into an integrated healthcare system. Applicants should propose research that advances the field of interventional radiology and evaluates the cost, cost-effectiveness, and quality outcomes of IR interventions. Period of Support One-time award Funds/Direct Costs Up to $30,000 total costs Program Contact Society of Interventional Radiology (800) 488-7284 American Society of Hematology (ASH) Junior Faculty Scholar Awards May 7, 2014 Letter of Intent Due Date: August 1, 2014 Application Due Date: "http://www.hematology.org/Awards/Scholar/2407.aspx" About The American Society of Hematology (ASH) Scholar Awards are designed to support hematologists who have chosen a career in research by providing partial salary or other support during that critical period required for completion of training and achievement of status as an independent investigator. Letters of Intent (LOI) are required and due by May 7, 2014. Applications will be made available to applicants who successfully submit LOI by the deadline on June 5, 2014. Full applications are due by August 1, 2014. SCCC Research Administration Period of Support Up to 3 years Funds/Direct Costs $75,000 total costs per year Budgetary Notes Up to 15% of the award can be (but is not required to be) used for benefits, including medical and dental insurance, life insurance and retirement benefits Program Contact ASH (202) 776-0544 [email protected] North American Neuroendocrine Tumor Society (NANETS) Young Investigator Award June 30, 2014 Application Due Date: "http://www.nanets.net/research/2014-young-investigatoraward-criteria" About The purpose of the NANETS Young Investigator Award is to encourage investigators at the end of their fellowship or beginning of their faculty appointment to pursue basic and/or translational research focused on neuroendocrine tumors. Candidates must be in the first 5 years of a faculty appointment (instructor, research scientist or above) in an accredited medical school or other institution in North America and must be a NANETS members. Period of Support 1 year Funds/Direct Costs $50,000 total costs for 1 year Program Contact NANETS (360) 314-4112 American Institute For Cancer Research Investigator Initiated Grants January 27, 2014 Letter of Intent Due Date: May 12, 2014 Application Due Date: "http://www.aicr.org/research/grant/research_funded_grant_ programs.html" About The American Institute for Cancer Research (AICR) Grant Program is dedicated to funding research on cancer prevention, treatment and survival through food, nutrition, physical activity and weight management. This program aims to increase understanding of the cancer process, including cancer initiation, promotion, progression and metastasis. Letters of Intent (LOI) are required and due by January 27, 2014. Selected applications will be invited to submit full proposals, if invited, full proposals are due by May 12, 2014. Period of Support Up to 2 years; 3 years for special start up grants Funds/Direct Costs $75,000 per year direct costs Budgetary Notes 10% indirect costs are allowed Program Contact Research Department (202) 328-7744 [email protected] April 2014 Funding Newsletter Page 7 of 49 Ovarian Cancer Research Fund, Inc. Liz Tilberis Early Career Award May 6, 2014 Application Due Date: "http://www.ocrf.org/wp-content/uploads/2015-Tilberis-LOIRFP.pdf" About The Liz Tilberis Scholars Program is directed towards junior faculty with a strong commitment to an investigative career in the field of ovarian cancer research. The intent of these awards is to support a substantial time commitment to research and academic endeavors in ovarian cancer. Period of Support 3 years Funds/Direct Costs $150,000 direct costs per year for 3 years Budgetary Notes Indirect costs are not allowed Program Contact Sarah DeFeo (212) 268-1002 [email protected] American Institute for Cancer Research Matching Grants January 27, 2014 Letter of Intent Due Date: May 12, 2014 Application Due Date: "http://www.aicr.org/research/grant/research_funded_grant_ programs.html" About The American Institute for Cancer Research (AICR) Grant Program is dedicated to funding research on cancer prevention, treatment and survival through food, nutrition, physical activity and weight management (body fatness). This program aims to increase understanding of the cancer process, including cancer initiation, promotion, progression and metastasis. AICR is interested in working with for-profit corporations and/or not-forprofit organizations in funding cancer research consistent with AICR’s areas of interest. Letters of Intent (LOI) are required and due by January 27, 2014. Selected applications will be invited to submit full proposals. If invited, full proposals are due by May 12, 2014. Period of Support Not specified Funds/Direct Costs $75,000 total direct costs Program Contact Research Department (202) 328-7744 [email protected] Period of Support Up to 1 year Funds/Direct Costs $50,000 direct costs per year Budgetary Notes Indirect costs are not allowed Program Contact Doctors Cancer Foundation [email protected] Lung Cancer Research Foundation (LCRF) Research Grants June 16, 2014 Application Due Date: "http://www.lungcancerresearchfoundation.org/ourresearch/current-grants/" About Grants are awarded for lung cancer projects focused on: basic science, translational research, clinical research, supportive care, and quality of care/outcomes. Grant requests can include new project submissions as well as requests for renewal of current funding. The submissions are evaluated according to the standard NIH guidelines for scientific merit and originality of concept by the Medical Advisory Board of LCRF. Period of Support Up to 1 year Funds/Direct Costs $50,000 total costs per year Program Contact LCRF (212) 588-1580 [email protected] Children’s Leukemia Research Association Research Grant Program June 30, 2014 Application Due Date: "http://www.childrensleukemia.org/researchgrants.html" About The sponsor funds research grants for investigators who are conducting the most promising research into leukemia, in the hopes of isolating the causes and finding a cure for this disease. Period of Support 1 year Funds/Direct Costs $30,000 total costs per year Program Contact Research Grant Department (516) 222-1944 [email protected] Department of Defense Breast Cancer Research Program (BCRP) Innovator Award Doctors Cancer Foundation Research Grant May 31, 2014 Application Due Date: "http://doctorscancerfoundation.org/id4.html" Preliminary Application Due: May 14, 2014 August 15, 2014 Application Due Date: "http://cdmrp.army.mil/funding/pa/14bcrpinnov_pa.pdf" About The sponsor provides support for the best program for the management of cancer. There is a strong interest in cancer stem cells, microRNAi agents, epigenetic agents, as well as many others. The sponsor is particularly interested in promoting the best of the young scientists. The project should be innovative, sound and be able to lead to clinical trials. About The Innovator Award supports visionary individuals who have demonstrated creativity, innovative work, and leadership in any field including, but not limited to, breast cancer. The Innovator Award will provide these individuals with the funding and freedom to pursue their most novel, visionary, high-risk ideas that could ultimately lead to ending breast cancer. The PI must commit at least 50% of SCCC Research Administration April 2014 Funding Newsletter Page 8 of 49 his/her full-time professional effort during the award period to breast cancer research. Preliminary applications are due by May 14, 2014. The sponsor will invite selected applicants to submit full proposals. If invited, full applications are due by August 15, 2014. Period of Support Up to 5 years Funds/Direct Costs $5M direct costs for entire period of support Program Contact Congressionally Directed Medical Research Program (301) 682-5507 [email protected] Ovarian Cancer Research Fund, Inc. Ann Schreiber Mentored Investigator Award May 6, 2014 Application Due Date: "http://www.ocrf.org/wp-content/uploads/2015-AnnSchreiber-LOI-RFP.pdf" About This grant provides funding for trainees who are working under the supervision of a mentor who is a recognized leader in the field of ovarian cancer research. Period of Support Up to 2 years Funds/Direct Costs $75,000 total costs over entire period of support Program Contact Sarah DeFeo (212) 268-1002 [email protected] North American Neuroendocrine Tumor Society (NANETS) Clinical Investigator Scholarship June 30, 2014 Application Due Date: "http://www.nanets.net/research/2014-ncis-scholarshipcriteria" About The purpose of the NANETS Clinical Investigator Scholarship is to encourage clinicians at the end of their fellowship or beginning of their faculty appointment to pursue a clinical career focused on neuroendocrine tumors. Candidates must be in the first 5 years of a faculty appointment (instructor or above) in an accredited medical school or other institution in North America (must be on staff at time of award) and must be a NANETS members. Period of Support 1 year Funds/Direct Costs $50,000 total costs for 1 year Program Contact NANETS (360) 314-4112 SCCC Research Administration Department of Defense Breast Cancer Research Program (BCRP) Breakthrough Award Levels 1 and 2 Preliminary Application Due: May 14, 2014 May 28, 2014 Application Due Date: "http://cdmrp.army.mil/funding/pa/14bcrpbreakthrough12_pa .pdf" About The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are: --Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must be significant and move beyond an incremental advancement. Applications must articulate the pathway to making a clinical impact for individuals with, or at risk for, breast cancer, even if clinical impact is not an immediate outcome. --Research Scope: Research proposed under this award mechanism may be small- to large-scale projects, at different stages of idea and research development. Pre-applications are required and must be received by May 14, 2014. The sponsor will invite selected applicants to submit full proposals. If invited, full proposals must be received by May 28, 2014. Period of Support 3 years Funds/Direct Costs Level 1: $350,000 direct costs over 3 years; Level 2: $700,000 direct costs over 3 years Congressionally Directed Medical Program Contact Research Program (301) 682-5507 [email protected] Alex's Lemonade Stand Foundation Reach Awards May 30, 2014 Application Due Date: "http://www.alexslemonade.org/grants/guidelines" About Our Reach Awards are designed to move hypothesisdriven research toward the clinic. The goal of this award is to support selected "late translational" studies needed to ultimately initiate a clinical trial. A successful application will identify an unmet clinical need relevant to the care of pediatric cancer patients and describe how the proposed project will allow for the pre-clinical research to be translated to the clinic while keeping broader clinical testing and implementation in view. Period of Support 2 years Funds/Direct Costs $125,000 total costs per year Program Contact Alex's Lemonade Stand Foundation (610) 649-3034 April 2014 Funding Newsletter Page 9 of 49 Alex's Lemonade Stand Foundation "A" Award May 23, 2014 Application Due Date: "http://www.alexslemonade.org/grants/guidelines" About This grant is designed for young scientists who want to jump-start their career in pediatric oncology research. The ideal candidate has an original project that is not currently being funded. Demonstration of outstanding mentorship and a future commitment to pediatric cancer investigation are critical components of a successful application. initiation of promising new projects or novel ideas by junior faculty members. Applicants should be within six years of their first independent research or faculty appointment and must not currently hold any peer review funding. Period of Support 1 year Funds/Direct Costs $45,000 total costs for 1 year Program Contact Nicole Ruiz (305) 243-3029 [email protected] Program Announcements (PA) Period of Support 3 years Funds/Direct Costs $450,000 total costs over entire period of support Program Contact Alex's Lemonade Stand Foundation Wynnewood (610) 649-3034 Multiple Institutes, including the National Cancer Institute Understanding and Promoting Health Literacy (R01) PAR-13-130 Intramural Funding Opportunities Deadline: June 5, 2014 "http://grants.nih.gov/grants/guide/pa-files/PAR-13-130.html" Sylvester Comprehensive Cancer Center Sylvester Acceleration Clinical Trial Grants 2014 Deadline: June 18, 2014 "http://sylvester.org/research/funding-opportunities" About The goal of this program is to support the development of highly innovative, programmatically important investigator initiated, cooperative group or industry sponsored therapeutic trials. While investigator initiated trials continue to be a high priority, and historically have been underfunded, other types of trials may also test concepts of high value to the programs of the Cancer Center and to the community of cancer patients. In order to rapidly accrue to our cancer clinical trials, funds will be provided to accelerate trials that are highly competitive. Only Cancer Center Faculty Members may apply. Trials may focus on any type of cancer. The trial must have received PRC approval to be considered. Period of Support 1 year Funds/Direct Costs $100,000 total costs for 1 year to cover patient costs and IRB fees Nicole Ruiz Program Contact (305) 243-3029 [email protected] American Cancer Society (ACS) Institutional Research Grant - Pilot Projects Grant May 30, 2014 Application Due Date: "http://sylvester.org/research/funding-opportunities" About The American Cancer Society Institutional Research Grant (ACS IRG) - Pilot Projects Grant is providing funds for meritorious cancer research that cannot be readily supported through other funding mechanisms. The primary purpose of the ACS grant is to provide seed funds for the SCCC Research Administration About The goal of this program announcement is to encourage methodological, intervention and dissemination research for understanding and promoting health literacy. Health literacy is defined as the degree to which individuals have the capacity to obtain, process, and understand basic health information and services needed to make appropriate health decisions. This FOA utilizes the NIH Research Project Grant (R01) grant mechanism. Period of Support 5 years Funds/Direct Costs Application budgets are not limited, but need to reflect the actual needs of the proposed project Program Contact Wen-Ying Sylvia Chou (240) 276-6954 [email protected] Multiple Institutes, including the National Cancer Institute Mechanisms, Models, Measurement, & Management in Pain Research (R01) PA-13-118 Deadline: June 5, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PA-13-118.html" About New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioral and social sciences. Although great strides have been made in some areas, such as the identification of neural pathways of pain, the experience of pain and the challenge of treatment have remained uniquely individual and unsolved. Furthermore, our understanding of how and why individuals transition to a chronic pain state after an acute injury is limited. Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from April 2014 Funding Newsletter Page 10 of 49 underrepresented, minority, disabled, or women investigators. This program will use the NIH Research Project (R01) award mechanism. Period of Support 5 years Funds/Direct Costs No limit is set on the costs requested by R01 applicants but awards will be appropriately tailored to the proposed work Program Contact Susan Marden 6701 Democracy Boulevard Suite 710 Bethesda, MD 20892-4870 (301) 496-9623 [email protected] Multiple Institutes, including the National Cancer Institute Obesity Policy Evaluation Research (R01) PA-13-110 Deadline: June 5, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-13-110.html" About This Funding Opportunity Announcement (FOA) encourages Research Project Grant (R01) applications that propose to evaluate large scale policy or programs that are expected to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. The National Cancer Institute is particularly interested in the evaluation of programs or policies that may affect dietary or physical activity behavior and/or weight, and studies incorporating economic research. This FOA utilizes the NIH Research Project Grant (R01) grant mechanism. Period of Support 5 years Funds/Direct Costs Application budgets are not limited, but need to reflect actual needs of the proposed project Program Contact Sonia Arteaga (301) 435-6677 [email protected] Multiple Institutes, including the National Cancer Institute Mechanistic Insights from Birth Cohorts (R01) PAR-13-109 Deadline: June 5, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PAR-13109.html" About The sponsors invite applications for novel research on how prenatal exposures contribute to the etiology of chronic diseases and health conditions later in life. The goal of this award is to stimulate research by leveraging existing birth cohorts to address targeted mechanistic questions regarding the normal and abnormal SCCC Research Administration developmental origins of organ systems and/or diseases of interest to the participating NIH Institutes and Centers. This FOA will utilize the NIH Research Project (R01) grant mechanism. Period of Support Up to 5 years Funds/Direct Costs $500,000 direct costs per year Program Contact Corinne M. Silva (301) 451-7335 [email protected] Multiple Institutes, including the National Cancer Institute Potential Effects of Metformin on Aging and AgeRelated Conditions: Small-Scale Clin Studies and Secondary Analysis of Controlled Clin Studies (R01) PA-12-271 Deadline: June 5, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-12-271.html" About Emerging data from clinical studies of metformin in a variety of patient populations suggest that it may have other effects, besides being an antihyperglycemic agent, which warrant further attention in translational aging research. The objective of this Funding Opportunity Announcement (FOA) is to support research projects that include smallscale physiologic studies in humans or secondary analyses of data and/or stored biospecimens from controlled clinical intervention studies, to increase our understanding about the clinical translational potential of metformin to delay deleterious aging changes or to extend healthy human life span. This includes identification of specific populations particularly likely to benefit, and/or to obtain information on metformin’s human physiologic and cellular effects that would be useful in identifying novel molecular targets. This FOA utilizes the NIH (R01) Research Project Grant mechanism. Period of Support Up to 5 years Funds/Direct Costs Application budgets are not limited, but need to reflect actual needs of the proposed project Program Contact Chhanda Dutta, PhD 31 Center Drive, MSC 2292 Bethesda, MD 20892 (301) 435-3048 [email protected] National Cancer Institute Examination of Survivorship Care Planning Efficacy and Impact (R01) PA-12-275 Deadline: June 5, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PA-12-275.html" April 2014 Funding Newsletter Page 11 of 49 About The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research to evaluate the effect of care planning on cancer survivors' health and psychosocial outcomes; self-management of late effects and adherence to cancer screening and health behavior guidelines; utilization of follow-up care; organizational-level factors influencing the implementation of care planning; and associated costs. Specifically, the FOA aims to stimulate research that will: 1) develop and test metrics for evaluating the impact of survivorship care planning; 2) evaluate the impact of survivorship care planning on cancer survivors' morbidity, self-management and adherence to care recommendations, utilization of follow-up care, and on systems outcomes, such as associated costs and impact on organizations implementing care planning; and 3) identify models and processes of care that promote effective survivorship care planning. The ultimate goal of this FOA is to generate a body of science that will inform the development and delivery of interventions and best practices in follow-up care for cancer survivors. This FOA utilizes the NIH (R01) Research Project Grant mechanism. Period of Support Up to 5 years Funds/Direct Costs Application budgets are not limited, but need to reflect actual needs of the proposed project Program Contact Stephen Hunt Taplin (240) 276-6947 [email protected] Multiple Institutes, including the National Cancer Institute Bioengineering Research Grants (BRG) (R01) PAR-13-137 Deadline: June 5, 2014 "http://grants.nih.gov/grants/guide/pa-files/PAR-13-137.html" About The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach that can increase our understanding of and solve problems in biological, clinical or translational science. This FOA utilizes the NIH Research Project Grant (R01) grant mechanism. Period of Support Up to 5 years Funds/Direct Costs Application budgets are not limited, but need to reflect actual needs of the proposed project Program Contact Houston Baker (240) 276-5908 [email protected] SCCC Research Administration Multiple Institutes, including the National Cancer Institute Development of Assays for High-Throughput Screening for Use in Probe and Pre-therapeutic Discovery (R01) PAR-13-364 Deadline: June 5, 2014 "http://grants.nih.gov/grants/guide/pa-files/PAR-13-364.html" About The participating NIH Institutes and Centers invite Research Project Grant (R01) applications to develop assays for high throughput screening (HTS) for use in Probe and Pre-therapeutic Discovery. The NCI is interested in development of assays to identify or evaluate small molecules for use in elucidating molecular, cellular, or in vivo mechanisms or processes of probable or known importance to cancer biology, and for use in developing strategies for cancer prevention, diagnosis, treatment or clinical monitoring of treatment. Assays proposed may be biochemical, cellular or model organism-based, and may be useful for discovering small molecule probes, preventive or therapeutic drug leads, or imaging agent leads. Applicants may find the NCI Developmental Therapeutics Program (http://dtp.nci.nih.gov) resources to be helpful. Collaborations between laboratories with screen development capabilities and laboratories with small molecule synthesis capabilities are encouraged. This FOA utilizes the NIH Research Grants (R01) award mechanism. Period of Support 3 years Funds/Direct Costs Application budgets are not limited, but need to reflect the actual needs of the proposed project Program Contact Suzanne Forry-Schaudies (240) 276-5922 [email protected] Multiple Institutes, including the National Cancer Institute Accelerating the Pace of Drug Abuse Research Using Existing Data (R01) PAR-13-080 Deadline: June 5, 2014 "http://grants.nih.gov/grants/guide/pa-files/PAR-13-080.html" About The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing the innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of drug using behaviors (defined as alcohol, tobacco, prescription and other drug) and related disorders. Under this FOA, the National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Cancer Institute (NCI), and the Office of Behavioral and Social Sciences Research (OBSSR) encourage the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, April 2014 Funding Newsletter Page 12 of 49 trajectories of drug using behaviors and their consequences, risk and resilience. This FOA will utilize the NIH Research Project (R01) grant mechanism. Period of Support Up to 3 years Funds/Direct Costs $150,000 direct costs per year Program Contact Marsha F. Lopez 6001 Executive Boulevard, Rm. 5144, MSC 9589 Bethesda, MD 20892-9589 (301) 443-6504 [email protected] Multiple Institutes, including the National Cancer Institute Academic-Industrial Partnerships for Translation of in vivo Imaging Systems for Cancer Investigations (R01) PAR-13-169 Deadline: June 5, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PAR-13169.html" About National Cancer Institute (NCI) invites applications from research partnerships formed by academic and industrial investigators to accelerate the translation of either preclinical or clinical in vivo imaging systems and/or methods that are designed to solve a targeted cancer problem. The proposed imaging system/methods may include single or multi modality in vivo imaging and spectroscopy systems, image-guided and drug delivery systems, image analysis, and related research resources. This FOA utilizes the NIH Research Project Grant (R01) grant mechanism. Period of Support Up to 5 years Funds/Direct Costs The amount of funds requested and their distribution between years should be tailored to the needs of the project, usually less than $500,000 in total direct costs in any one year of the project Program Contact Houston Baker (240) 276-5908 [email protected] Multiple Institutes, including the National Cancer Institute Innovative Research Methods: Prevention and Management of Symptoms in Chronic Illness (R01) PA-13-165 Deadline: June 5, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-13-165.html" SCCC Research Administration About This funding opportunity seeks to update the randomized control trial (RCT) design using novel research methods that are practical, innovative, and hold promise for producing more effective outcomes. Novel clinical research designs, applied to symptom management trials, may identify those treatment strategies that best alter the course of symptom burden in chronic illness by addressing the issues of varied treatment responses across patients, subject retention, and adherence to treatment regimens. This FOA will utilize the NIH Research Project Grant (R01) award mechanism. Period of Support Up to 4 years Funds/Direct Costs Application budgets are not limited, but need to reflect the actual needs of the proposed project Budgetary Notes R01 Applications with budgets of $350,000 or less in direct costs per year are encouraged Program Contact Emily Tran (240) 276-6324 [email protected] Multiple Institutes, including the National Cancer Institute Chronic Inflammation and Age-related Disease (R01) PAR-13-233 Deadline: June 5, 2014 "http://grants.nih.gov/grants/guide/pa-files/PAR-13-233.html" About Applications are invited to address both the origins and the effects of low level chronic inflammation in the onset and progression of age-related diseases and conditions. Chronic inflammation, as defined by elevated levels of both local and systemic cytokines and other pro-inflammatory factors, is a hallmark of aging in virtually all higher animals including humans and is recognized as a major risk factor for developing age-associated diseases. A clear understanding of how chronic inflammation compromises the integrity of cells or tissues leading to disease progression is lacking. Thus, there is a critical need to establish the knowledge base that will allow a better understanding of the complex interplay between inflammation and age-related diseases. Applications submitted to this FOA should aim to clarify the molecular and cellular basis for the increase in circulating inflammatory factors with aging, and/or shed light on the cause-effect relationship between inflammation and disease, using pre-clinical (animal or cellular based) models. This FOA utilizes the NIH Research Grants (R01) grant mechanism. April 2014 Funding Newsletter Page 13 of 49 Period of Support Up to 5 years Funds/Direct Costs Application budgets are not limited, but need to reflect the actual needs of the proposed project Program Contact Ron Johnson (240) 276-6228 [email protected] Multiple Institutes, including the National Cancer Institute Research to Characterize and Reduce Stigma to Improve Health (R01) PA-13-248 Deadline: June 5, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-13-248.html" About The National Cancer Institute encourages research focused on associations between experienced stigma and biological cancer outcomes; associations between stigma and stress, negative affectivity, and/ or social isolation; ways in which health disparities are exacerbated or perpetuated by stigma. It also encourages research on the health and economic impact of other forms of discrimination, including racial or ethnic discrimination or discrimination arising from lower socioeconomic status, as well as stigma associated with cancer. Another area of interest concerns the influence of stigma on process of care behaviors and medical decisions (e.g., willingness to seek preventive services), particularly among cultures with cancer-related stigma convictions (e.g., Vietnamese and other Asian American populations). Other areas of research include but are not limited to factors that contribute to the internalization of a stigmatized identity; studies that address the role of compounding or interactive stigmatized identities; and, factors that may attenuate or buffer against stigma or stigma-related consequences (e.g., positive affectivity, social support). Of particular interest are intervention or health communication studies aimed at targeting cancer-related stigma and methodological studies aimed at improving detection of cancer-related stigmas. This FOA utilizes the NIH Research Project Grant (R01) award mechanism. Period of Support 5 years Funds/Direct Costs Application budgets are not limited, but need to reflect the actual needs of the proposed project Program Contact Luis A. Salicrup (240) 276-5810 [email protected] About The purpose of this Funding Opportunity Announcement (FOA) is to invite qualified basic science and clinical investigators to submit applications for research projects designed to advance the understanding of pathogenic mechanisms underlying systemic amyloidosis, to develop improved techniques (in particular those that are noninvasive) for the clinical detection and diagnosis of systemic amyloid diseases, to develop novel cellular and in vivo models with which to identify candidate therapeutic agents, and to evaluate the clinical efficacy of novel therapies designed to prevent, arrest, and (when possible) reverse the morbid and lethal progression of these diseases. The National Cancer Institute (NCI) is interested in sponsoring research relevant to the diagnosis and treatment of Amyloid Light-chain (AL) Amyloidosis, particularly that relating to the characterization, detection, and control or elimination of clonal plasma cell disorders that underlie this form of amyloidosis. This FOA utilizes the NIH Research Project Grant (R01) award mechanism. Period of Support Up to 5 years Funds/Direct Costs Application budgets are not limited, but need to reflect the actual needs of the proposed project Program Contact Rebekah Rasooly (301) 594-6007 [email protected] Multiple Institutes, including the National Cancer Institute Research on the Health of LGBTI Populations (R01) PA-12-111 Deadline: June 5, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-12-111.html" About The National Institutes of Health (NIH) is committed to supporting research that will increase scientific understanding of the health status of various population groups and improve the effectiveness of health interventions and services for individuals within those groups. High priority is placed on research on populations that appear to have distinctive health risk profiles but have received insufficient attention from investigators. This Funding Opportunity Announcement (FOA) highlights a particular community: lesbian, gay, bisexual, transgender, intersex, and related populations (designated here as LGBTI populations). Basic, social, behavioral, clinical, and services research relevant to the missions of the sponsoring Institutes and Centers may be proposed. This FOA utilizes the NIH Research Project Grant (R01) grant mechanism. Multiple Institutes, including the National Cancer Institute Systemic Amyloidosis: Basic, Translational, and Clinical Research (R01) PA-13-286 Deadline: June 5, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PA-13-286.html" SCCC Research Administration April 2014 Funding Newsletter Page 14 of 49 Period of Support Up to 5 years Funds/Direct Costs Application budgets are not limited, but need to reflect actual needs of the proposed project Program Contact Rebecca Liddell Huppi, PhD 31 Center Drive, Suite 3A33 Bethesda, MD 20892-2440 (301) 496-4995 [email protected] Multiple Institutes, including the National Cancer Institute Behavioral and Social Science Research on Understanding and Reducing Health Disparities (R01) PA-13-292 Deadline: June 5, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-13-292.html" About The purpose of this FOA is to encourage behavioral and social science research on the causes and solutions to health and disabilities disparities in the U. S. population. Health disparities between, on the one hand, racial/ethnic populations, lower socioeconomic classes, and rural residents and, on the other hand, the overall U.S. population are major public health concerns. Emphasis is placed on research in and among three broad areas of action: 1) public policy, 2) health care, and 3) disease/disability prevention. Particular attention is given to reducing “health gaps” among groups. Applications that utilize an interdisciplinary approach, investigate multiple levels of analysis, incorporate a life-course perspective, and/or employ innovative methods such as systems science or community-based participatory research are particularly encouraged. This FOA utilizes the NIH Research Grants (R01) award mechanism. Period of Support Up to 5 years Funds/Direct Costs Application budgets are not limited but need to reflect the actual needs of the proposed project Program Contact Shobha Srinivasan (240) 276-6938 [email protected] Multiple Institutes, including the National Cancer Institute Translational Research at the Aging/Cancer Interface (TRACI) (R01) PA-12-136 Deadline: June 5, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-12-136.html" About This Funding Opportunity Announcement (FOA) encourages translational research proposals in the overlapping areas of human aging and cancer, linking basic and clinical research relevant to the care of older cancer SCCC Research Administration patients through both bench-to-bedside and bedside-tobench approaches. Ultimately, information from the research supported by this initiative should improve the health and well-being of elderly patients at risk for, or diagnosed with, cancer and decrease the functional impairment and morbidity associated with cancer in this population. This FOA utilizes the Research Project Grant (R01) grant mechanism. Period of Support Up to 5 years Funds/Direct Costs Application budgets are not limited, but need to reflect actual needs of the proposed project Program Contact Kevin Howcroft (301) 496-7815 [email protected] Multiple Institutes, including the National Cancer Institute Modeling Social Behavior (R01) PAR-13-374 Deadline: June 5, 2014 "http://grants.nih.gov/grants/guide/pa-files/PAR-13-374.html" About This Funding Opportunity Announcement (FOA) encourages applications for developing and testing innovative theories and computational, mathematical, or engineering approaches to deepen our understanding of complex social behavior. This research will examine phenomena at multiple scales to address the emergence of collective behaviors that arise from individual elements or parts of a system working together. Emergence can also describe the functioning of a system within the context of its environment. Often properties we associate with a system itself are in actuality properties of the relationships and interactions between a system and its environment. This FOA will support research that explores the often complex and dynamic relationships among the parts of a system and between the system and its environment in order to understand the system as a whole. To accomplish the goals of this initiative, we encourage applications that build transdisciplinary teams of scientists spanning a broad range of expertise. Minimally this team should include investigators with expertise in the behavioral or social sciences as well as in computational and systems modeling (computer science, mathematics, engineering, or other systems sciences). Applications should demonstrate bridgebuilding between disciplines, scales and levels. This FOA utilizes the NIH Research Grants (R01) award mechanism. Period of Support Up to 5 years Funds/Direct Costs Application budgets are not limited but need to reflect the actual needs of the proposed project Program Contact William Riley (240) 276-6973 [email protected] April 2014 Funding Newsletter Page 15 of 49 Multiple Institutes, including the National Cancer Institute Quantitative Imaging for Evaluation of Response to Cancer Therapies (U01) PAR-14-116 Deadline: June 5, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PAR-14116.html" About The National Cancer Institute (NCI) invites applications which are expected to enhance the value of quantitative imaging (QI) in clinical trials for prediction and/or measurement of response to cancer therapies. One avenue for this enhancement is to emphasize the development, optimization and validation of state-of-the-art QI methods and software tools for potential implementation in single site phase 1 or 2 clinical trials. The second avenue to enhance QI methods is to address the challenges of integrating existing and or new QI methods as required for multicenter phase 3 clinical trials. This may involve evaluation of a range of multimodal imaging approaches, harmonization of image data collection, analysis, display and clinical workflow methods across imaging platforms, or testing their performance across different cancer sites. Because this validation process is complex, a single research program cannot be expected to complete every detail from initial tool development to final integration into clinical trials. Therefore, it is anticipated that these research goals will require multidisciplinary efforts. Although the involvement of industrial partners in the development of the QI methods is not required, it is strongly encouraged. Awardees will also join the Quantitative Imaging Network (QIN) to share ideas and approaches in order to validate and standardize imaging data and related imaging metadata for quantitative measurements of prediction and/or response to cancer therapies. This FOA will utilize the NIH (U01) cooperative agreement award mechanism. Period of Support up to 5 years Funds/Direct Costs Up to $500,000 direct costs per year Program Contact Robert Nordstrom (240) 276-5934 [email protected] National Cancer Institute Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01) PAR-12-228 Deadline: June 5, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PAR-12228.html" About National Cancer Institute (NCI) invites applications for transdisciplinary and translational research that will identify specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications must test the effects of SCCC Research Administration physical activity or weight control or both interventions on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research, which may include but are not limited to interventioninduced changes in sex hormones, insulin or insulin-like growth factors or their binding proteins, insulin resistance, glucose metabolism, leptin and other adipokines, immunologic or inflammatory factors, oxidative stress and DNA damage or repair capacity, angiogenesis, or prostaglandins. This research will require transdisciplinary approaches that bring together behavioral intervention expertise, cancer biology, and other basic and clinical science disciplines relevant to the pathways being studied. This FOA will use the NIH Research Project (R01) award mechanism. Period of Support 5 years Funds/Direct Costs No limit is set on the costs requested by R01 applicants however, costs should be appropriately tailored to the proposed work Program Contact Catherine M. Alfano (240) 276-6736 [email protected] Multiple Institutes, including the National Cancer Institute Ethical Legal and Social Implications (ELSI) of Genomic Research Regular Research Program (R01) PA-11-250 Deadline: June 5, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-11-250.html" About This Funding Opportunity Announcement (FOA) encourages applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. The NCI is interested in empirical research that focuses on the ethical, legal and social issues related to heritable cancer syndromes. Study of the psycho-social and behavioral impact on affected individuals, their families and populations and research that takes into consideration the perspectives of diverse racial, ethnic and socioeconomic backgrounds, as well as children, older adults and people with disabilities is highly desirable. The ultimate goal of this research will be to improve outcomes related to the diagnosis of heritable cancer syndromes. This FOA will utilize the NIH Research Project Grant (R01) award mechanism. Period of Support Up to 5 years Funds/Direct Costs Application budgets are not limited, but need to reflect actual needs of the proposed project Program Contact Charlisse Caga-Anan (240) 276-6738 [email protected] April 2014 Funding Newsletter Page 16 of 49 Multiple Institutes, including the National Cancer Institute Research on Malignancies in the Context of HIV/AIDS (R01) PA-13-377 Deadline: May 7, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PA-13-377.html" About National Cancer Institute (NCI) and National Institute of Dental and Craniofacial Research (NIDCR) invite applications from institutions/organizations that propose to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying Human Immunodeficiency (HIV) infection or Acquired Immune Deficiency Syndrome (AIDS). The NCI and NIDCR encourage research in areas such as the study of the etiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both non-AIDS defining and AIDS-defining malignancies in diverse populations. This FOA encourages research efforts that will (i) provide information on the clinical outcomes of such cancers in the HIV-infected population and (ii) identify specific contributions resulting from HIV infection and its potential interaction with other pathogens for the development and pathogenesis of these cancers. Ultimately, such efforts could inform screening approaches and therapies targeted to the HIV-infected population. This program utilizes the NIH Research Project (R01) award mechanism. Period of Support 5 years Funds/Direct Costs Application budgets are not limited but, costs should be appropriately tailored to the proposed work Program Contact Geraldina Dominguez (301) 496-3204 [email protected] Multiple Institutes, including the National Cancer Institute Research on Malignancies in the Context of HIV/AIDS (R21) PA-13-378 Deadline: May 7, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-13-378.html" About This funding opportunity announcement (FOA) encourages Research Project Grant (R21) applications from institutions/organizations that propose to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying Human Immunodeficiency (HIV) infection or Acquired Immune Deficiency Syndrome (AIDS). The National Cancer Institute encourages research in areas such as the study of the etiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both non-AIDS defining and AIDS-defining malignancies in diverse populations. This FOA encourages research efforts that will (i) provide SCCC Research Administration information on the clinical outcomes of such cancers in the HIV-infected population and (ii) identify specific contributions resulting from HIV infection and its potential interaction with other pathogens for the development and pathogenesis of these cancers. Ultimately, such efforts could inform screening approaches and therapies targeted to the HIV-infected population. This FOA utilizes the NIH Exploratory/Developmental Research Grant (R21) award mechanism. Period of Support Up to 2 years Funds/Direct Costs $275,000 total costs over entire period of support Budgetary Notes No more than $200,000 may be requested in any single year Program Contact Geraldina Dominguez (301) 496-3204 [email protected] Multiple Institutes, including the National Cancer Institute Interventions for Health Promotion and Disease Prevention in Native American Populations (R01) PAR-11-346 Deadline: May 15, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PAR-11346.html" About The purpose of this Funding Opportunity Announcement (FOA) is to develop, adapt, and test the effectiveness of health promotion and disease prevention interventions in Native American (NA) populations. The National Cancer Institute (NCI) is interested in applications that focus on both individual and community interventions relating to primary and secondary (screening) cancer prevention. It is important that researchers consider the context in which people live and develop interventions that can improve overall health and result in better health outcomes as they relate to cancer. The intervention program should be designed so that it could be sustained within the entire community within existing resources, and, if successful, disseminated in other Native American communities. The long-term goal of this FOA is to reduce mortality and morbidity in NA communities. For the purposes of this FOA Native Americans include the following populations: Alaska Native, American Indian, and Native Hawaiian. This FOA will utilize the NIH (R01) Research Project Grant award mechanism. Period of Support Up to 5 years Funds/Direct Costs Application budgets are not limited, but need to reflect actual needs of the proposed project Program Contact Shobha Srinivasan (240) 276-6938 [email protected] April 2014 Funding Newsletter Page 17 of 49 Multiple Institutes, including the National Cancer Institute Specialized Programs of Research Excellence (SPOREs) in Human Cancer for Year 2014 (P50) PAR-14-031 Deadline: May 20, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PAR-14031.html" within 5-10 years. This FOA utilizes the NIH Research Project Grant (R01) funding mechanism. Period of Support 5 years Funds/Direct Costs Application budgets are not limited but need to reflect the actual needs of the proposed project Program Contact Houston Baker (240) 276-5908 [email protected] About The program will fund Specialized Programs of Research Excellence (SPORE) grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer (or a related group of cancers). SPOREs are expected not only to conduct a wide spectrum of research activities, but also to contribute significantly to the development of specialized shared resource core facilities (cores), improved research model systems, and collaborative research projects with other institutions. The research supported through this program must be translational in nature and must always be focused upon knowledge of human biology stemming from research using cellular, molecular, structural, biochemical, and/or genetic experimental approaches with the goal of a translational human endpoint within the 5 year term of the grant. In addition, SPOREs must include both a Developmental Research Program for pilot studies and a Career Development Program to foster careers in organbased translational science. This Funding Opportunity Announcement (FOA) utilizes the NIH Specialized Center Grant (P50) award mechanism. About National Cancer Institute (NCI) invites applications for investigator-initiated program project (P01) grants. Proposed program projects may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer treatment, cancer diagnosis, cancer prevention, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each Program Project application must consist of at least three component projects. The component projects must share a common central theme, focus, and/or overall objective. This FOA will utilize the NIH Program Project (P01) grant mechanism. Period of Support Up to 5 years Funds/Direct Costs Up to $2.5M total costs per year Program Contact Toby T. Hecht, PhD (301) 496-8528 [email protected] Period of Support 5 years Funds/Direct Costs Unspecified Program Contact Referral Officer (240) 276-6390 [email protected] Multiple Institutes, including the National Cancer Institute Bioengineering Research Partnerships (BRP) R01 PAR-14-092 Multiple Institutes, including the National Cancer Institute Behavioral Interventions to Address Multiple Chronic Health Conditions in Primary Care (R01) PA-14-114 Deadline: May 20, 2014 "http://grants.nih.gov/grants/guide/pa-files/PAR-14-092.html" About This Funding Opportunity Announcement (FOA) encourages bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important biomedical research problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine. Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing these technologies and engage biomedical researchers or clinicians throughout the project. The goal of the program is to support projects that can realize meaningful solutions SCCC Research Administration National Cancer Institute National Cancer Institute Program Project (P01) Applications PAR-13-321 Deadline: May 25, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PAR-13321.html" Deadline: June 5, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-14-114.html" About This funding opportunity announcement (FOA) seeks Research Project Grant (R01) applications that propose to use a common conceptual model to develop behavioral interventions to modify health behaviors and improve health outcomes in patients with comorbid chronic diseases and health conditions. Specifically, this FOA will support research in primary care that uses a multi-disease care management approach to behavioral interventions with high potential impact to improve patient-level health outcomes for individuals with three or more chronic health conditions. The proposed approach must modify behaviors using a common approach rather than administering a distinct intervention for each targeted behavior and/or April 2014 Funding Newsletter Page 18 of 49 condition. Diseases and health conditions can include, but are not limited to: mental health disorders (e.g., depression), diabetes, smoking, obesity, chronic pain, alcohol and substance abuse and dependence, chronic obstructive pulmonary disorder, cancer and hypertension. This FOA utilizes the NIH Research Project Grant (R01) award mechanism. Period of Support Up to 5 years Funds/Direct Costs Application budgets are not limited but need to reflect the actual needs of the proposed project Program Contact Veronica Chollette (301) 435-2837 [email protected] NEW National Cancer Institute Early Phase Clinical Trials in Imaging and ImageGuided Interventions (R01) PAR-14-166 Deadline: June 30, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PAR-14166.html" About The National Cancer Institute (NCI) invites applications for clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided therapy, contrast kinetic modeling, 3-D reconstruction and other quantitative tools. As many such preliminary evaluations are early in development, this FOA will provide investigators with support for pilot (Phase I and II) cancer imaging clinical trials, including patient monitoring and laboratory studies. This FOA supports novel uses of known/standard clinical imaging agents and methods as well as the evaluation of new agents, systems, or methods. The imaging and image guided intervention (IGI) investigations, if proven successful in these early clinical trials, can then be validated in larger studies through competitive R01 mechanisms, or through clinical trials in the Specialized Programs of Research Excellence (SPOREs), Cancer Centers and/or the NCI's National Clinical Trials Network. This FOA utilizes the NIH Research Project (R01) award mechanism. Period of Support 3 years Funds/Direct Costs $5000,000 direct costs over entire period of support Budgetary Notes No more than $250,000 in direct costs may be requested in any single year Program Contact Lori A. Henderson (240) 276-5930 [email protected] SCCC Research Administration Multiple Institutes, including the National Cancer Institute Improving Diet and Physical Activity Assessment (R01) PAR-12-198 Deadline: June 5, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PAR-12198.html" About This Funding Opportunity Announcement (FOA) encourages innovative research to enhance the quality of measurements of dietary intake and physical activity. Applications submitted under this FOA may include development of: novel assessment approaches; better methods to evaluate instruments; assessment tools for culturally diverse populations or various age groups, including older adults; improved technology or applications of existing technology; statistical methods to assess or correct for measurement errors or biases, methods to investigate the multidimensionality of diet and physical activity behavior through pattern analysis; or integrated measurement of diet and physical activity along with the environmental context of such behaviors. This FOA utilizes the Research Project Grant (R01) grant mechanism. Period of Support Up to 5 years Funds/Direct Costs Up to $650,000 direct costs per year Program Contact Amy Subar, PhD 6130 Executive Boulevard, Room 4005 Bethesda, MD 20892-7344 (301) 594-0831 [email protected] Multiple Institutes, including the National Cancer Institute Mechanisms of Alcohol-Associated Cancers (R01) PA-12-146 Deadline: June 5, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-12-146.html" About This Funding Opportunity Announcement (FOA) invites applications from researchers with broad ranges of expertise to study the mechanisms by which alcohol increases cancer risk. Target sites for alcohol-related carcinogenesis include the oral cavity, pharynx, esophagus, larynx, breast, liver, and colon. A better understanding of the molecular basis by which alcohol increases cancer risk could lead to improved therapeutic approaches and preventative strategies and would provide guidance on safe levels of alcohol consumption. The goal of this program announcement is to stimulate a broad range of research into the mechanisms by which alcohol contributes to carcinogenesis. This FOA utilizes the NIH Research Project Grant (R01) award mechanism. April 2014 Funding Newsletter Page 19 of 49 Period of Support Up to 5 years Funds/Direct Costs Application budgets are not limited, but need to reflect actual needs of the proposed project Program Contact Sharon Ross, PhD 6130 Executive Boulevard, Room 3157 Rockville, MD 20852 (301) 594-7547 [email protected] About This Funding Opportunity Announcement (FOA) encourages applications to validate the clinical utility of new molecular diagnostics for determining prognosis or predicting response to therapy or toxicity for cancer. This program will support research projects to improve clinical decision-making in the care of cancer patients and as such will support studies that use tumor specimens linked to specific treatment and clinical outcome information. This FOA is not appropriate for molecular diagnostics discovery projects. This FOA utilizes the NIH Research Project Grant (R01) mechanism. Multiple Institutes, including the National Cancer Institute Biomechanisms of Peripheral Nerve Damage by Anti-Cancer Therapy (R01) PA-12-082 Period of Support Up to 5 years Funds/Direct Costs Application budgets are not limited, but need to reflect actual needs of the proposed project Program Contact Magdalena Thurin, PhD (301) 496-1591 [email protected] Deadline: June 5, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-12-082.html" About The purpose of this Funding Opportunity Announcement (FOA) is to encourage basic biologic research on damage to the peripheral nervous system instigated by pharmacologic cancer treatments, known as chemotherapyinduced peripheral neuropathy (CIPN). This FOA intends to stimulate neuroscience researchers to apply their expertise from studying neuropathies focused on diabetic and inherited diseases to the injuries incurred by cancer treatments. More data is necessary to understand the mechanisms of neuronal damage and to identify the targets instrumental to CIPN initiation and maintenance. Preclinical research that focuses not only on peripheral neuropathic pain but also on neurosensory symptoms such as paresthesias and peripheral anesthesias is invited. The ultimate goal of this FOA is to lead to a molecular understanding of CIPN that allows for the rational development of interventions that will treat or prevent CIPN. This FOA utilizes the NIH Research Project Grant (R01) grant mechanism. About This Funding Opportunity Announcement (FOA) encourages research projects for the development and validation of biomarkers for: a) early detection, prediction of progression, and recurrence of hematopoietic malignancies, especially in high-risk individuals; and, b) for risk assessment of primary and secondary hematopoietic malignancies. This FOA also encourages the development and improvement of specific technologies and methods for quantitative detection of novel biomarkers associated with hematopoietic malignancies. This FOA utilizes the NIH Research Project (R01) award mechanism. Period of Support Up to 5 years Funds/Direct Costs Application budgets are not limited, but need to reflect actual needs of the proposed project Program Contact Joanna M. Brell, MD 6130 Executive Boulevard, Room 2014 Bethesda (301) 496-8541 [email protected] Period of Support Up to 5 years Funds/Direct Costs Application budgets are not limited, but need to reflect actual needs of the proposed project Program Contact Lynn Sorbara 6130 Executive Boulevard, Room 3137 Bethesda, MD 20892-7362 (301) 435-0584 [email protected] National Cancer Institute Validation of Molecular Diagnostics to Predict Patient Outcomes Using Specimens from MultiSite Cancer Trials (R01) PA-12-013 National Cancer Institute Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (R43/R44) PAR-13-327 Deadline: June 5, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PA-12-013.html" Deadline: May 28, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PAR-13327.html" SCCC Research Administration National Cancer Institute Biomarkers for Early Detection of Hematopoietic Malignancies (R01) PA-12-221 Deadline: June 5, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PA-12-221.html" April 2014 Funding Newsletter Page 20 of 49 About National Cancer Institute (NCI) invites applications for Small Business Innovation Research (SBIR) from small business concerns (SBCs) proposing research for commercial development of novel cancer-relevant technologies. The proposed research projects are expected to focus on the development of highly-innovative technologies that improve molecular and/or cellular analysis of cancer with a significant likelihood for either overcoming persistent challenges or obstacles or opening entirely new fields for cancer research or clinical care. Applications should specify milestones relevant to both the development and commercialization of these technologies. This FOA complements the goals of the NCI's Innovative Molecular Analysis Technologies (IMAT) program by facilitating the path towards technology commercialization. Prior participation in the IMAT Program is not required for eligibility for this FOA. Applications are expected to indicate the significant attributes and advantages of the proposed technology over currently available technologies and conventional approaches. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications. Period of Support 6 months for Phase I and 2 years for Phase II Funds/Direct Costs Up to $225,000 for Phase I and $1,500,000 for Phase II total costs for entire period of support Program Contact Amir Rahbar (240) 276-5230 [email protected] National Cancer Institute Identifying Non-coding RNA Targets for Early Detection of Cancer (R01) PA-12-213 Deadline: June 5, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PA-12-213.html" About This Funding Opportunity Announcement (FOA) encourages research projects on non-coding RNAs (ncRNAs) and their targets in preneoplastic lesions and early stage cancers. This FOA also encourages research projects to assess the usefulness of stable microRNAs (miRNAs) and ncRNAs to predict progression to cancer and as biomarkers for early cancer detection and screening. Building on both basic and biomarker research on microRNAs (miRNA), this FOA will further promote research on all classes of ncRNAs and support the translation of stable miRNAs into cancer screening or diagnostic tests. This FOA utilizes the NIH Research Project (R01) grant mechanism. SCCC Research Administration Period of Support Up to 5 years Funds/Direct Costs Application budgets are not limited, but need to reflect actual needs of the propsed project Program Contact Wendy Wang 6130 Executive Boulevard, Room 3138 Bethesda, MD 20852-7362 (301) 594-7607 [email protected] Multiple Institutes, including the National Cancer Institute Spatial Uncertainty: Data, Modeling, and Communication (R01) PA-11-238 Deadline: June 5, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-11-238.html" About The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research that identifies sources of spatial uncertainty (i.e., inaccuracy or instability of spatial or geographic information) in public health data, incorporates the inaccuracy or instability into statistical methods, and develops novel tools to visualize the nature and consequences of spatial uncertainty. The National Cancer Institute (NCI) is interested in general methodology of spatial statistical models and visualization tools that are applicable to disease control and prevention especially as related to cancer and cancer patients. This FOA utilizes the NIH Research Project Grant (R01) grant mechanism. Period of Support Up to 5 years Funds/Direct Costs Application budgets are not limited, but need to reflect actual needs of the proposed project Program Contact Li Zhu, PhD (301) 594-6546 [email protected] Multiple Institutes, including the National Cancer Institute Systems Science and Health in the Behavioral and Social Sciences (R01) PAR-11-314 Deadline: June 5, 2014 "http://grants.nih.gov/grants/guide/pa-files/PAR-11-314.html" About This Funding Opportunity Announcement (FOA) encourages applications that propose to develop basic and applied projects utilizing systems science methodologies relevant to human behavioral and social sciences and health. This FOA is intended to encourage a broader scope of topics to be addressed with systems science methodologies, beyond those encouraged by existing open FOAs. Research projects applicable to this FOA are those that are either applied or basic in nature (including methodological development), have a human behavioral April 2014 Funding Newsletter Page 21 of 49 and/or social science focus, and feature systems science methodologies. NCI is interested in research projects that address the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients. This FOA utilizes the NIH Research Project Grant (R01) award mechanism. Period of Support Up to 5 years Funds/Direct Costs Application budgets are not limited, but need to reflect actual needs of the proposed project Program Contact Kara L. Hall, PhD (240) 276-6831 [email protected] Multiple Institutes, including the National Cancer Institute Solicitation of Assays for High Throughput Screening (HTS) to Discover Chemical Probes (R01) PAR-12-058 Deadline: June 5, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PAR-12058.html" About This Funding Opportunity Announcement (FOA) encourages investigators to form collaborations with an established academic, nonprofit, or commercial high throughput screening (HTS) facility that has the requisite expertise and experience to implement HTS-ready assays for the discovery and development of small molecule chemical probes. Through this FOA, the NCI is interested in high throughput screens intended to identify small molecules for use in elucidating molecular, cellular, or in vivo mechanisms or processes of probable or known importance to cancer biology, and for use in developing strategies for cancer prevention, diagnosis, treatment or clinical monitoring of treatment. Screens may be biochemical, cellular or model organism-based. High throughput screens for targets that address unmet needs in cancer prevention, treatment or diagnosis are encouraged. This FOA utilizes the NIH Research Project Grant (R01) award mechanism. Period of Support Up to 3 years Funds/Direct Costs Application budgets are not limited, but need to reflect actual needs of the propsed project Program Contact Suzanne Forry-Schaudies, PhD (301) 435-9147 [email protected] SCCC Research Administration Multiple Institutes, including the National Cancer Institute Solicitation of Validated Hits for the Discovery of in vivo Chemical Probes (R01) PAR-12-060 Deadline: June 5, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PAR-12060.html" About This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes. It is expected that applicants will have in hand the starting compounds (“validated hits”) for chemical optimization and bioassays for testing new analog compounds. Through this FOA, the NCI is particularly interested in validated hits for targets that address unmet needs in the prevention, treatment, or diagnosis of cancer. Strategies that include testing of in vivo chemical probe activity in primary human tumor cells are encouraged. This FOA utilizes the NIH Research Project Grant (R01) award mechanism. Period of Support Up to 3 years Funds/Direct Costs Application budgets are not limited, but need to reflect actual needs of the proposed project Program Contact Suzanne Forry-Schaudies, PhD (301) 435-9147 [email protected] Multiple Institutes, including the National Cancer Institute Dissemination and Implementation Research in Health (R01) PAR-13-055 Deadline: June 5, 2014 "http://grants.nih.gov/grants/guide/pa-files/PAR-13-055.html" About This FOA encourages investigators to submit research grant applications that will identify, develop, and refine effective and efficient methods, structures, and strategies that test models to disseminate and implement researchtested health behavior change interventions and evidencebased prevention, early detection, diagnostic, treatment, and quality of life improvement services into public health and clinical practice settings. This FOA will use the NIH Research Project Grant (R01) award mechanism. Period of Support Up to 5 years Funds/Direct Costs Application budgets are not limited, but need to reflect actual needs of the proposed project Program Contact David A. Chambers (301) 443-3747 [email protected] April 2014 Funding Newsletter Page 22 of 49 Multiple Institutes, including the National Cancer Institute Advancing the Science of Geriatric Palliative Care (R21) PA-13-355 Deadline: June 16, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PA-13-355.html" About This Funding Opportunity Announcement (FOA) encourages research grant applications focused on palliative care in geriatric populations. This FOA emphasizes studies in a variety of settings including ambulatory care, hospitals (and specific sites within hospitals including specialty wards, intensive care units and emergency departments), assisted living facilities, and short- and long-term care facilities; however, hospice and end-of-life settings are not included within the scope of this FOA, as they are the subject of other NIH programs. Rather, this FOA highlights research on palliative care in settings and at time points earlier in geriatric patients' disease or disability trajectories. Types of studies may include observational, quasi-experimental, or interventional studies using primary data collection and/or secondary analyses. Leveraging on-going cohorts, intervention studies, networks, data and specimen repositories, and other existing resources and infrastructure are encouraged. NCI’s focus includes studies that identify factors that contribute to tolerance of and adherence to cancer therapies and improved enrollment and retention in clinical trials. This FOA utilizes the NIH (R21) Exploratory/ Developmental Research Grant award mechanism. Period of Support 2 years Funds/Direct Costs $275,000 direct costs for entire period of support Budgetary Notes No more than $200,000 may be requested in any single year Program Contact Basil Eldadah (301) 496-6761 [email protected] Multiple Institutes, including the National Cancer Institute Biomechanisms of Peripheral Nerve Damage by Anti-Cancer Therapy (R21) PA-12-083 Deadline: June 16, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-12-083.html" About The purpose of this Funding Opportunity Announcement (FOA) is to encourage basic biologic research on damage to the peripheral nervous system instigated by pharmacologic cancer treatments, known as chemotherapyinduced peripheral neuropathy (CIPN). This FOA intends to stimulate neuroscience researchers to apply their expertise from studying neuropathies focused on diabetic and inherited diseases to the injuries incurred by cancer treatments. More data is necessary to understand the mechanisms of neuronal damage and to identify the targets SCCC Research Administration instrumental to CIPN initiation and maintenance. Preclinical research that focuses not only on peripheral neuropathic pain but also on neurosensory symptoms such as paresthesias and peripheral anesthesias is invited. The ultimate goal of this FOA is to lead to a molecular understanding of CIPN that allows for the rational development of interventions that will treat or prevent CIPN. This FOA utilizes the NIH Exploratory/Developmental (R21) Research Grant Award mechanism. Period of Support Up to 2 years Funds/Direct Costs $275,000 direct costs for entire period of support, up to $200,000 direct costs allowed in any single year Program Contact Joanna M. Brell, MD (301) 496-8541 [email protected] Multiple Institutes, including the National Cancer Institute Research on the Health of LGBTI Populations (R03) PA-12-112 Deadline: June 16, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-12-112.html" About The National Institutes of Health (NIH) is committed to supporting research that will increase scientific understanding of the health status of various population groups and improve the effectiveness of health interventions and services for individuals within those groups. High priority is placed on research on populations that appear to have distinctive health risk profiles but have received insufficient attention from investigators. This Funding Opportunity Announcement (FOA) highlights a particular community: lesbian, gay, bisexual, transgender, intersex, and related populations (designated here as LGBTI populations). Basic, social, behavioral, clinical, and services research relevant to the missions of the sponsoring Institutes and Centers may be proposed. This FOA utilizes the NIH Small Grant Program (R03) award mechanism. Period of Support Up to 2 years Funds/Direct Costs $50,000 direct costs per year Program Contact Rebecca Liddell Huppi PhD 31 Center Drive, Suite 3A33 Bethesda, MD 20892-2440 (301) 496-4995 [email protected] Multiple Institutes, including the National Cancer Institute Research on the Health of LGBTI Populations (R21) PA-12-113 Deadline: June 16, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-12-113.html" April 2014 Funding Newsletter Page 23 of 49 About The National Institutes of Health (NIH) is committed to supporting research that will increase scientific understanding of the health status of various population groups and improve the effectiveness of health interventions and services for individuals within those groups. High priority is placed on research on populations that appear to have distinctive health risk profiles but have received insufficient attention from investigators. This Funding Opportunity Announcement (FOA) highlights a particular community: lesbian, gay, bisexual, transgender, intersex, and related populations (designated here as LGBTI populations). Basic, social, behavioral, clinical, and services research relevant to the missions of the sponsoring Institutes and Centers may be proposed. This FOA utilizes the NIH Exploratory/Developmental Research Grant Award (R21) mechanism. Period of Support Up to 2 years Funds/Direct Costs $275,000 direct costs for entire period of support, up to $200,000 direct costs allowed in any single year Program Contact Rebecca Liddell Huppi 31 Center Drive, Suite 3A3 (301) 496-4995 [email protected] National Cancer Institute Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21) PAR-12-229 Deadline: June 16, 2014 "http://grants.nih.gov/grants/guide/pa-files/PAR-12-229.html" About This Funding Opportunity Announcement (FOA) encourages transdisciplinary and translational research that will identify specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications must test the effects of physical activity or weight control or both interventions on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research, which may include but are not limited to intervention-induced changes in sex hormones, insulin or insulin-like growth factors or their binding proteins, insulin resistance, glucose metabolism, leptin and other adipokines, immunologic or inflammatory factors, oxidative stress and DNA damage or repair capacity, angiogenesis, or prostaglandins. This research will require transdisciplinary approaches that bring together behavioral intervention expertise, cancer biology, and other basic and clinical science disciplines relevant to the pathways being studied. This FOA utilizes the NIH Exploratory/ Developmental Research Grant Award (R21) mechanism. SCCC Research Administration Period of Support Up to 2 years Budgetary Notes $275,000 direct costs over entire period of support, with no more than $200,000 requested in any single year Program Contact Catherine M. Alfano, PhD (240) 276-6736 [email protected] National Cancer Institute Examination of Survivorship Care Planning Efficacy and Impact (R21) PA-12-274 Deadline: June 16, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PA-12-274.html" About The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research to evaluate the effect of care planning on cancer survivors' health and psychosocial outcomes; self-management of late effects and adherence to cancer screening and health behavior guidelines; utilization of follow-up care; organizational-level factors influencing the implementation of care planning; and associated costs. Specifically, the FOA aims to stimulate research that will: 1) develop and test metrics for evaluating the impact of survivorship care planning; 2) evaluate the impact of survivorship care planning on cancer survivors' morbidity, self-management and adherence to care recommendations, utilization of follow-up care, and on systems outcomes, such as associated costs and impact on organizations implementing care planning; and 3) identify models and processes of care that promote effective survivorship care planning. The ultimate goal of this FOA is to generate a body of science that will inform the development and delivery of interventions and best practices in follow-up care for cancer survivors. This FOA utilizes the NIH Exploratory/Developmental Research Grant (R21) Award mechanism. Period of Support Up to 2 years Funds/Direct Costs $275,000 direct costs over entire period of support, up to $200,000 may be requested in any single year Program Contact Stephen Hunt Taplin (240) 276-6947 [email protected] Multiple Institutes, including the National Cancer Institute Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21) PA-12-284 Deadline: June 16, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-12-284.html" April 2014 Funding Newsletter Page 24 of 49 About The purpose of this Funding Opportunity Announcement (FOA) is to encourage Exploratory/Developmental Bioengineering Research Grants (EBRG) applications which establish the feasibility of technologies, techniques or methods that: 1) explore a unique multidisciplinary approach to a biomedical challenge; 2) are high-risk but have a considerable pay-off; and 3) develop data which can lead to significant future research. An EBRG application may propose hypothesis-driven, discovery-driven, developmental, or design-directed research and is appropriate for evaluating unproven approaches for which there is minimal or no preliminary data. This FOA utilizes the NIH Exploratory/ Developmental Research Grant Award (R21) mechanism. Period of Support 3 years Funds/Direct Costs Up to $300,000 direct costs per year Program Contact NIH grant resources (301) 435-0714 [email protected] Period of Support Up to 2 years Funds/Direct Costs $275,000 direct costs over entire period of support, with up to $200,000 in direct costs allowed in any single year Program Contact Houston Baker, PhD (240) 276-5908 [email protected] About The goal of this program announcement is to encourage methodological, intervention and dissemination research for understanding and promoting health literacy. Health literacy is defined as the degree to which individuals have the capacity to obtain, process, and understand basic health information and services needed to make appropriate health decisions. This FOA utilizes the NIH Research Grant (R03) mechanism. NEW Period of Support 2 years Funds/Direct Costs $50,000 total costs per year Program Contact Wen-ying Sylvia Chou (240) 276-6954 [email protected] Multiple Institutes, including the National Cancer Institute Early Stage Development of Technologies in Biomedical Computing, Informatics, and Big Data Science (R01) PA-14-155 Deadline: June 5, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-14-155.html" About The NIH is interested in promoting a broad base of research and development of technologies in biomedical computing, informatics, and Big Data Science that will support rapid progress in areas of scientific opportunity in biomedical research. It is expected that this research and development is conducted in the context of important biomedical and behavioral research problems. As such, applications are intended to develop enabling technologies that could apply to the interests of most NIH Institutes and Centers and range from basic biomedicine and including research to all relevant organ systems and diseases. Major themes of research include collaborative environments; data integration; analysis and modeling methodologies; and novel computer science and statistical approaches. New opportunities are also emerging as large and complex data sets are becoming increasingly available to the research community. This initiative aims to address biomedical research areas in biomedical computing, informatics, and Big Data science through the early stage development of new software, tools and related resources, as well as the fundamental research (e.g., methodologies and approaches) leading up to that development. This FOA utilizes the NIH (R01) Research Project award mechanism. SCCC Research Administration Multiple Institutes, including the National Cancer Institute Understanding and Promoting Health Literacy (R03) PAR-13-131 Deadline: June 16, 2014 "http://grants.nih.gov/grants/guide/pa-files/PAR-13-131.html" Multiple Institutes, including the National Cancer Institute Advancing the Science of Geriatric Palliative Care (R01) PA-13-354 Deadline: June 5, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PA-13-354.html" About This Funding Opportunity Announcement (FOA) encourages research grant applications focused on palliative care in geriatric populations. This FOA emphasizes studies in a variety of settings including ambulatory care, hospitals (and specific sites within hospitals including specialty wards, intensive care units and emergency departments), assisted living facilities, and short- and long-term care facilities; however, hospice and end-of-life settings are not included within the scope of this FOA, as they are the subject of other NIH programs. Rather, this FOA highlights research on palliative care in settings and at time points earlier in geriatric patients' disease or disability trajectories. Types of studies may include observational, quasi-experimental, or interventional studies using primary data collection and/or secondary analyses. Leveraging on-going cohorts, intervention studies, networks, data and specimen repositories, and other existing resources and infrastructure are encouraged. NCI’s focus includes studies that identify factors that contribute to tolerance of and adherence to cancer therapies and improved enrollment and retention in clinical April 2014 Funding Newsletter Page 25 of 49 trials. This FOA utilizes the NIH (R01) Research Project Grant award mechanism. Period of Support Up to 5 years Funds/Direct Costs Application budgets are not limited, but need to reflect the actual needs of the proposed project Program Contact Basil Eldadah (301) 496-6761 [email protected] Multiple Institutes, including the National Cancer Institute Innovative Research Methods: Prevention and Management of Symptoms in Chronic Illness (R21) PA-13-167 Deadline: June 16, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-13-167.html" About This funding opportunity seeks to update the randomized control trial (RCT) design using novel research methods that are practical, innovative, and hold promise for producing more effective outcomes. Novel clinical research designs, applied to symptom management trials, may identify those treatment strategies that best alter the course of symptom burden in chronic illness by addressing the issues of varied treatment responses across patients, subject retention, and adherence to treatment regimens. This FOA will utilize the NIH Research Grant (R21) funding mechanism. Period of Support 2 years Funds/Direct Costs $275,000 direct costs over two years Budgetary Notes No more than $200,000 in direct costs allowed in any single year Program Contact Silvia P. Torres (240) 276-6322 [email protected] Multiple Institutes, including the National Cancer Institute Research to Characterize and Reduce Stigma to Improve Health (R21) PA-13-246 Deadline: June 16, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-13-246.html" About The National Cancer Institute encourages research focused on associations between experienced stigma and biological cancer outcomes; associations between stigma and stress, negative affectivity, and/ or social isolation; ways in which health disparities are exacerbated or perpetuated by stigma. It also encourages research on the health and economic impact of other forms of discrimination, including racial or ethnic discrimination or discrimination arising from lower socioeconomic status, as well as stigma associated with cancer. Another area of interest concerns the influence of stigma on process of care SCCC Research Administration behaviors and medical decisions (e.g., willingness to seek preventive services), particularly among cultures with cancer-related stigma convictions (e.g., Vietnamese and other Asian American populations). Other areas of research include but are not limited to factors that contribute to the internalization of a stigmatized identity; studies that address the role of compounding or interactive stigmatized identities; and, factors that may attenuate or buffer against stigma or stigma-related consequences (e.g., positive affectivity, social support). Of particular interest are intervention or health communication studies aimed at targeting cancer-related stigma and methodological studies aimed at improving detection of cancer-related stigmas. This FOA utilizes the NIH (R21) award mechanism. Period of Support 2 years Funds/Direct Costs $275,000 direct costs for the entire period of support, no more than $200,000 may be requested in any single year Program Contact Luis A. Salicrup (240) 276-5810 [email protected] Multiple Institutes, including the National Cancer Institute Research to Characterize and Reduce Stigma to Improve Health (R03) PA-13-247 Deadline: June 16, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-13-247.html" About The National Cancer Institute encourages research focused on associations between experienced stigma and biological cancer outcomes; associations between stigma and stress, negative affectivity, and/ or social isolation; ways in which health disparities are exacerbated or perpetuated by stigma. It also encourages research on the health and economic impact of other forms of discrimination, including racial or ethnic discrimination or discrimination arising from lower socioeconomic status, as well as stigma associated with cancer. Another area of interest concerns the influence of stigma on process of care behaviors and medical decisions (e.g., willingness to seek preventive services), particularly among cultures with cancer-related stigma convictions (e.g., Vietnamese and other Asian American populations). Other areas of research include but are not limited to factors that contribute to the internalization of a stigmatized identity; studies that address the role of compounding or interactive stigmatized identities; and, factors that may attenuate or buffer against stigma or stigma-related consequences (e.g., positive affectivity, social support). Of particular interest are intervention or health communication studies aimed at targeting cancer-related stigma and methodological studies aimed at improving detection of cancer-related stigmas. This FOA utilizes the NIH Research Grants Award (R03) April 2014 Funding Newsletter Page 26 of 49 Period of Support 2 years Funds/Direct Costs $100,000 direct costs for entire period of support, no more than $50,000 in direct costs may be requested in any single year Program Contact Luis A. Salicrup (240) 276-5810 [email protected] Multiple Institutes, including the National Cancer Institute Solicitation of Assays for High Throughput Screening (HTS) to Discover Chemical Probes (R21) PAR-12-059 Deadline: June 16, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PAR-12059.html" About This Funding Opportunity Announcement (FOA) encourages investigators to form collaborations with an established academic, nonprofit, or commercial high throughput screening (HTS) facility that has the requisite expertise and experience to implement HTS-ready assays for the discovery and development of small molecule chemical probes. Through this FOA, the NCI is interested in high throughput screens intended to identify small molecules for use in elucidating molecular, cellular, or in vivo mechanisms or processes of probable or known importance to cancer biology, and for use in developing strategies for cancer prevention, diagnosis, treatment or clinical monitoring of treatment. Screens may be biochemical, cellular or model organism-based. High throughput screens for targets that address unmet needs in cancer prevention, treatment or diagnosis are encouraged. This FOA utilizes the NIH Exploratory/ Developmental Research Grant (R21) award mechanism. Period of Support Up to 2 years Funds/Direct Costs $275,000 direct costs for entire period of support, up to $200,000 direct costs allowed in any single year Program Contact Suzanne Forry-Schaudies, PhD (301) 435-9147 [email protected] Multiple Institutes, including the National Cancer Institute Behavioral and Social Science Research on Understanding and Reducing Health Disparities (R21) PA-13-288 About The purpose of this FOA is to encourage behavioral and social science research on the causes and solutions to health and disabilities disparities in the U. S. population. Health disparities between, on the one hand, racial/ethnic populations, lower socioeconomic classes, and rural residents and, on the other hand, the overall U.S. population are major public health concerns. Emphasis is placed on research in and among three broad areas of action: 1) public policy, 2) health care, and 3) disease/disability prevention. Particular attention is given to reducing “health gaps” among groups. Applications that utilize an interdisciplinary approach, investigate multiple levels of analysis, incorporate a life-course perspective, and/or employ innovative methods such as systems science or community-based participatory research are particularly encouraged. This FOA utilizes the NIH Research Grants (R21) award mechanism. Period of Support 2 years Funds/Direct Costs $275,000 direct costs over entire period of support with no more than $200,000 in direct costs in any single year Program Contact Rina Das (240) 276-6184 [email protected] Multiple Institutes, including the National Cancer Institute Mechanisms, Models, Measurement and Management in Pain Research (R21) PA-13-119 Deadline: June 16, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PA-13-119.html" About New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioral and social sciences. Although great strides have been made in some areas, such as the identification of neural pathways of pain, the experience of pain and the challenge of treatment have remained uniquely individual and unsolved. Furthermore, our understanding of how and why individuals transition to a chronic pain state after an acute insult is limited. Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators. This program will use the NIH Exploratory/Developmental (R21) grant mechanism. Deadline: June 16, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-13-288.html" SCCC Research Administration April 2014 Funding Newsletter Page 27 of 49 Period of Support 2 years Funds/Direct Costs $275,000 direct costs over 2 years Budgetary Notes No more than $200,000 in direct costs allowed in any single year Program Contact Susan Marden 6701 Democracy Boulevard Suite 710 Bethesda, MD 20892-4870 (301) 496-9623 [email protected] Multiple Institutes, including the National Cancer Institute Advancing the Science of Geriatric Palliative Care (R03) PA-13-356 Deadline: June 16, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PA-13-356.html" About This Funding Opportunity Announcement (FOA) encourages research grant applications focused on palliative care in geriatric populations. This R03 announcement specifically encourages projects primarily aimed at collection of pilot data, demonstration of feasibility, development of new methodology, or other goals of limited scope requiring short-term support. This FOA emphasizes studies in a variety of settings including ambulatory care, hospitals (and specific sites within hospitals including specialty wards, intensive care units and emergency departments), assisted living facilities, and short- and longterm care facilities; however, hospice and end-of-life settings are not included within the scope of this FOA, as they are the subject of other NIH programs. Rather, this FOA highlights research on palliative care in settings and at time points earlier in geriatric patients' disease or disability trajectories. Types of studies may include observational, quasi-experimental, or pilot interventional studies using primary data collection and/or secondary analyses. Leveraging on-going cohorts, intervention studies, networks, data and specimen repositories, and other existing resources and infrastructure are encouraged. NCI’s focus includes studies that identify factors that contribute to tolerance of and adherence to cancer therapies and improved enrollment and retention in clinical trials. This FOA utilizes the NIH (R03) Small Grant Program award mechanism. Period of Support 2 years Funds/Direct Costs $50,000 direct costs per year Program Contact Basil Eldadah (301) 496-6761 [email protected] SCCC Research Administration Multiple Institutes, including the National Cancer Institute Bridging the Gap Between Cancer Mechanism and Population Science (U01) PAR-13-081 Deadline: June 17, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PAR-13081.html" About National Cancer Institute (NCI) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications for projects that bridge biological mechanism to population level scales. By incorporating insights and data from one end of the cancer research spectrum into the framework of the other, projects should be able to cross-validate data gathered at different scales, and explore links between basic biology, population science, and potential health applications in treatment, prevention, diagnosis, and/or screening. Proposed projects should pose a challenging cancer research question that can be addressed by connecting these two ends of the research spectrum that would be difficult to address or explain through biological or epidemiological investigation alone. Only a single cohesive project integrating aspects from these two areas is allowed in each application. This program will use the NIH (U01) Research Project Cooperative Agreements award mechanism. Period of Support Up to 5 years Funds/Direct Costs Up to $700,000 direct costs per year Program Contact Jennifer Couch (240) 276-6210 [email protected] National Cancer Institute Paul Calabresi Career Development Award for Clinical Oncology (K12) PAR-13-201 Deadline: June 18, 2014 "http://grants.nih.gov/grants/guide/pa-files/PAR-13-201.html" About This funding opportunity announcement (FOA) encourages applications for institutional research career development (K12) programs from applicant organizations that propose to promote the training and career development of clinical trials researchers. The purpose of the Paul Calabresi Career Development Award for Clinical Oncology (K12) is to increase the number of clinicians (M.D.s, D.O.s, Pharm.D.s, nurses with Ph.D.s or equivalent) and Ph.D. scientists who are trained to design and test clinical therapeutic research protocols (pilot/Phase I, Phase II, and Phase III clinical trials), conduct patient-oriented cancer therapeutic research in team research environments, and to support the career development of investigators who have made a commitment to focus their research endeavors on patient-oriented research. This program will use the NIH Mentored Clinical Scientist Development Program (K12) award mechanism. April 2014 Funding Newsletter Page 28 of 49 Funds/Direct Costs $750,000 total per year Budgetary Notes Direct costs are limited to $50,000 in the initial year of new (Type 1) programs Program Contact Mark Damico 6116 Executive Blvd Bethesda, MD 20892 (240) 276-5630 [email protected] investigate biological/genetic bases of cancer health disparities. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research and to provide resources for those investigators that may need additional support on their path to successfully compete for R01 funding in basic mechanistic research in understanding cancer health disparities. This FOA utilizes the NIH Exploratory/Developmental (R21) grant mechanism. Multiple Institutes, including the National Cancer Institute Image-guided Drug Delivery in Cancer (R01) PAR-13-185 Period of Support Up to 2 years Funds/Direct Costs $275,000 direct costs for entire period of support, up to $200,000 direct costs allowed in any single year Program Contact Phillip J. Daschner (240) 276-6227 [email protected] Deadline: June 19, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PAR-13185.html" About National Cancer Institute (NCI) and National Institute of Biomedical Imaging and Bioengineering (NIBIB) invite applications for innovative research projects that are focused on image-guided drug delivery (IGDD), including real-time image guidance, monitoring, quantitative in vivo characterizations and validation of delivery and response. It will support research in development of integrated imagingbased platforms for multifunctional and multiplexed drug delivery systems in cancer and other diseases, quantitative imaging assays of drug delivery, and early intervention. This FOA will use the NIH Research Project (R01) award mechanism. Period of Support 5 years Funds/Direct Costs No limit is set on the costs requested by R01 applicants but costs should be appropriately tailored to the proposed work Program Contact Keyvan Farahani 6116 Executive Boulevard Suite 300 Bethesda, MD 20892 (240) 276-5921 [email protected] Multiple Institutes, including the National Cancer Institute Exploratory/Developmental Grants Program for Basic Cancer Research in Cancer Health Disparities (R21) PAR-12-094 Deadline: June 20, 2014 "http://grants.nih.gov/grants/guide/pa-files/PAR-12-094.html" About This Funding Opportunity Announcement (FOA) invites grant applications from investigators interested in conducting basic research studies into the biological causes and mechanisms of cancer health disparities. These awards will support pilot and feasibility studies, development and testing of new methodologies, secondary data analyses, and innovative mechanistic studies that SCCC Research Administration Multiple Institutes, including the National Cancer Institute Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21) PAR-12-096 Deadline: June 20, 2014 "http://grants.nih.gov/grants/guide/pa-files/PAR-12-096.html" About This Funding Opportunity Announcement (FOA) invites applications by investigators from diverse backgrounds underrepresented in basic and biomedical cancer research. The NIH recognizes a unique and compelling need to promote diversity in the NIH-funded research workforce. The purpose of this FOA is to improve the diversity of the NCI-funded research workforce by supporting and recruiting eligible investigators from groups that have been shown to be underrepresented in the biomedical, clinical, behavioral, and social sciences including individuals from underrepresented racial and ethnic groups, individuals with disabilities, and individuals from socially, culturally, economically, or educationally disadvantaged backgrounds that have recently and demonstrably inhibited their ability to pursue a career in health-related research. This funding opportunity will also provide a bridge to investigators that have completed their research training and may need extra time to develop a research project grant application. This program utilizes the NIH Exploratory/Developmental (R21) grant mechanism. Period of Support Up to 2 years Funds/Direct Costs $275,000 direct costs for entire period of support, up to $200,000 direct costs allowed in any single year Program Contact Anil Wali, PhD (240) 276-6183 [email protected] April 2014 Funding Newsletter Page 29 of 49 Multiple Institutes, including the National Cancer Institute Basic Cancer Research in Cancer Health Disparities (U01) PAR-12-095 Deadline: June 20, 2014 "http://grants.nih.gov/grants/guide/pa-files/PAR-12-095.html" About This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biologic/genetic causes of cancer health disparities. These awards will support innovative studies designed to investigate biological/genetic bases of cancer disparities, and may include the development and testing of new methodologies and models, secondary data analyses, and mechanistic studies of identified biological factors associated with cancer disparities, including those related to basic research in prevention strategies. This FOA is also designed to aid and facilitate the development of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can develop resources and tools, such as biospecimens, cell lines and methods that are necessary to conduct basic research in cancer health disparities. This FOA utilizes the NIH Research Project – Cooperative Agreements (U01) grant mechanism. Period of Support Up to 5 years Funds/Direct Costs $250,000 direct costs per year Program Contact Phillip J. Daschner (240) 276-6227 [email protected] National Cancer Institute Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01) PAR-13-036 Deadline: June 20, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PAR-13036.html" About This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), encourages the submission of grant applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCOscreened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery SCCC Research Administration and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA. This FOA utilizes the NIH Research Project Cooperative Agreements (U01) award mechanism. Period of Support Up to 5 years Funds/Direct Costs Application budgets are not limited, but need to reflect actual needs of the proposed project Program Contact Claire Zhu (240) 276-7013 [email protected] Multiple Institutes, including the National Cancer Institute Innovative Research Methods: Prevention and Management of Symptoms in Chronic Illness (R15) PA-13-166 Deadline: June 25, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-13-166.html" About This funding opportunity seeks to update the randomized control trial (RCT) design using novel research methods that are practical, innovative, and hold promise for producing more effective outcomes. Novel clinical research designs, applied to symptom management trials, may identify those treatment strategies that best alter the course of symptom burden in chronic illness by addressing the issues of varied treatment responses across patients, subject retention, and adherence to treatment regimens. This FOA will utilize the NIH Academic Research Enhancement Award (R15) funding mechanism. Period of Support Up to 3 years Funds/Direct Costs $300,000 direct costs over 3 years Program Contact Susan Marden (301) 496-9623 [email protected] Multiple Institutes, including the National Cancer Institute Academic Research Enhancement Award (Parent R15) PA-13-313 Deadline: June 25, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-13-313.html" About The purpose of the Academic Research Enhancement Award (AREA) program is to stimulate research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation's research scientists, but that have not been major recipients of NIH support. AREA grants create opportunities for scientists and institutions, otherwise unlikely to participate extensively in NIH research programs, to contribute to the April 2014 Funding Newsletter Page 30 of 49 Nation's biomedical and behavioral research effort. AREA grants are intended to support small-scale research projects proposed by faculty members of eligible, domestic institutions, to expose students to meritorious research projects, and to strengthen the research environment of the applicant institution. This award utilizes the NIH (R15) Academic Research Enhancement Award (AREA) grant mechanism. Period of Support Up to 3 years Funds/Direct Costs Up to $300,000 direct costs for entire period of support Program Contact Christopher L. Hatch (240) 276-6454 [email protected] National Cancer Institute NCI Exploratory/Developmental Research Grant Program (NCI Omnibus R21) PAR-13-146 Deadline: June 27, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PAR-13146.html" About National Cancer Institute (NCI) invites applications for development of new research activities in all areas of cancer research. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (biomedical, behavioral, or clinical). This program will utilize the NIH Research Grant (R21) mechanism. Period of Support 2 years Funds/Direct Costs $275,000 direct costs over 2 years Budgetary Notes No more than $200,000 in direct costs allowed in any single year Program Contact National Cancer Institute (240) 276-6390 [email protected] National Cancer Institute NCI Small Grants Program for Cancer Research (NCI Omnibus R03) PAR-14-007 Deadline: June 27, 2014 "http://grants.nih.gov/grants/guide/pa-files/PAR-14-007.html" About This funding opportunity announcement (FOA), issued by the National Cancer Institute (NCI), of the National Institutes of Health (NIH) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, selfSCCC Research Administration contained research projects; development of research methodology; and development of new research technology. This FOA utilizes the NIH Research Grants (R03) funding mechanism. Period of Support 2 years Funds/Direct Costs $50,000 direct costs per year Program Contact National Cancer Institute (NCI) (240) 276-6390 [email protected] National Cancer Institute Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21) PAR-12-229 Deadline: June 16, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PAR-12229.html" About National Cancer Institute (NCI) invites applications for transdisciplinary and translational research that will identify specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications must test the effects of physical activity or weight control or both interventions on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research, which may include but are not limited to interventioninduced changes in sex hormones, insulin or insulin-like growth factors or their binding proteins, insulin resistance, glucose metabolism, leptin and other adipokines, immunologic or inflammatory factors, oxidative stress and DNA damage or repair capacity, angiogenesis, or prostaglandins. This research will require transdisciplinary approaches that bring together behavioral intervention expertise, cancer biology, and other basic and clinical science disciplines relevant to the pathways being studied. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism. Period of Support 2 years Funds/Direct Costs $275,000 direct costs over entire period of support with no more than $200,000 in direct costs allowed in any single year Program Contact Catherine M. Alfano (240) 276-6736 [email protected] Multiple Institutes, including the National Cancer Institute Improving Diet and Physical Activity Assessment (R21) PAR-12-197 Deadline: June 16, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PAR-12197.html" April 2014 Funding Newsletter Page 31 of 49 About This Funding Opportunity Announcement (FOA) encourages innovative research to enhance the quality of measurements of dietary intake and physical activity. Applications submitted under this FOA may include development of: novel assessment approaches; better methods to evaluate instruments; assessment tools for culturally diverse populations or various age groups, including children and older adults; improved technology or applications of existing technology; statistical methods to assess or correct for measurement errors or biases, methods to investigate the multidimensionality of diet and physical activity behavior through pattern analysis; or integrated measurement of diet and physical activity along with the environmental context of such behaviors. This program utilizes the NIH Exploratory/Developmental (R21) grant mechanism. Period of Support Up to 2 years Funds/Direct Costs $275,000 direct costs over entire period of support, up to $200,000 in direct costs allowed in any single year Program Contact Amy Subar, PhD 6130 Executive Boulevard, Room 4005 Bethesda, MD 20892-7344 (301) 594-0831 [email protected] National Cancer Institute NCI Mentored Patient-Oriented Research Career Development Award to Promote Diversity (K23) PAR-12-052 Deadline: June 12, 2014 "http://grants.nih.gov/grants/guide/pa-files/PAR-12-052.html" About The purpose of this award is to support the career development of investigators who have made a commitment to focus their research endeavors on patientoriented cancer research (POR). The award supports individuals with a health professional doctoral degree from groups currently underrepresented on a national level in the biomedical, clinical, behavioral, and social sciences. The NCI recognizes a unique and compelling need to promote diversity in the patient-oriented research workforce. This FOA utilizes the NIH Research Career Development (K23) grant mechanism. Period of Support Up to 5 years Funds/Direct Costs Up to $100,000 per year for salary, up to $30,000 per year in research development costs John O. Ojeifo, MD, PhD, MBA Program Contact (240) 276-6186 [email protected] SCCC Research Administration National Cancer Institute NCI Transition Career Development Award to Promote Diversity (K22) PAR-12-062 Deadline: June 12, 2014 "http://grants.nih.gov/grants/guide/pa-files/PAR-12-062.html" About The purpose of this award is to help ensure that a diverse pool of highly trained scientists are available in adequate numbers and in appropriate research areas to address the nation's biomedical, behavioral, and clinical research needs. Applications are invited from recipients of the NCI Mentored Career Development Award to Promote Diversity, or from advanced postdoctoral and/or newly independent research scientists representative of groups that are underrepresented in biomedical, behavioral, clinical, and/or social sciences. This award will provide "protected time" for recipients to develop and receive support for their initial cancer research program. This FOA utilizes the NIH Research Career Development (K22) grant mechanism. Period of Support Up to 3 years Funds/Direct Costs $100,000 per year toward salary, $50,000 per year for research development costs Program Contact Anil Wali, PhD (240) 276-6183 [email protected] National Cancer Institute Cancer Prevention, Control, Behavioral and Population Sciences Career Development Award (K07) PAR-12-067 Deadline: June 12, 2014 "http://grants.nih.gov/grants/guide/pa-files/PAR-12-067.html" About The purpose of the Cancer Prevention, Control, Behavioral Sciences, and Population Sciences Career Development Award is to support the career development of junior investigators with research or health professional doctoral degrees who want to become cancer-focused academic researchers in cancer prevention, cancer control, or the behavioral or population sciences. This Funding Opportunity Announcement (FOA) utilizes the NIH Academic Career Award (K07) mechanism. Period of Support Up to 5 years Funds/Direct Costs $100,000 per year for salary, $30,000 per year for research development costs Program Contact Susan Perkins (240) 276-5630 [email protected] April 2014 Funding Newsletter Page 32 of 49 National Cancer Institute NCI Established Investigator Award in Cancer Prevention and Control (K05) PAR-12-065 Deadline: June 12, 2014 "http://grants.nih.gov/grants/guide/pa-files/PAR-12-065.html" About The purpose of the NCI Established Investigator Award in Cancer Prevention and Control is to provide protected time to senior investigators with exceptional mentoring records and sustained, high levels of research productivity in cancer prevention, cancer control, or the behavioral or population sciences to devote to research and mentoring. This Funding Opportunity Announcement (FOA) utilizes the NIH Senior Scientist Award (K05) mechanism. Period of Support Up to 5 years Funds/Direct Costs Salary support of 25% of the institutional full-time staff appointment base salary and $25,000 per year direct costs resulting from mentored activities Program Contact Susan N. Perkins (240) 276-5630 [email protected] National Cancer Institute NCI Transition Career Development Award (K22) PAR-12-121 Deadline: June 12, 2014 "http://grants.nih.gov/grants/guide/pa-files/PAR-12-121.html" About This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent. This FOA utilizes the NIH (K22) Career Development Award mechanism. Period of Support Up to 3 years Funds/Direct Costs $100,000 per year salary plus fringe benefits, $50,000 in direct costs per year for research and development expenses Program Contact Sonia Jakowlew, PhD (240) 276-5630 [email protected] Multiple Institutes, including the National Cancer Institute NIH Pathway to Independence Award (Parent K99/R00) PA-14-042 About The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions, and to provide independent NIH research support during the transition that will help these individuals launch competitive, independent research careers. The NCI accepts K99/R00 applications that propose laboratory-based cancer research. This FOA utilizes the NIH (K99/R00) Career Transition Award/Research Transition Award funding mechanism. Period of Support 5 years Funds/Direct Costs $100,000 salary support plus fringe per year and $30,000 research support per year Program Contact Michael Schmidt (240) 276-5630 [email protected] Multiple Institutes, including the National Cancer Institute Understanding and Promoting Health Literacy (R21) PAR-13-132 Deadline: June 16, 2014 "http://grants.nih.gov/grants/guide/pa-files/PAR-13-132.html" About The goal of this program announcement is to encourage methodological, intervention and dissemination research for understanding and promoting health literacy. Health literacy is defined as the degree to which individuals have the capacity to obtain, process, and understand basic health information and services needed to make appropriate health decisions. This FOA utilizes the NIH Research Grant (R21) mechanism. Period of Support 2 years Funds/Direct Costs $275,000 over an R21 two-year period, up to $200,000 in direct costs allowed in any single year Program Contact Wen-Ying Sylvia Chou (240) 276-6954 [email protected] Multiple Institutes, including the National Cancer Institute Spatial Uncertainty: Data, Modeling, and Communication (R03) PA-11-240 Deadline: June 16, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-11-240.html" Deadline: June 12, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-14-042.html" SCCC Research Administration April 2014 Funding Newsletter Page 33 of 49 About The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research that identifies sources of spatial uncertainty (i.e., inaccuracy or instability of spatial or geographic information) in public health data, incorporates the inaccuracy or instability into statistical methods, and develops novel tools to visualize the nature and consequences of spatial uncertainty. The National Cancer Institute (NCI) is interested in general methodology of spatial statistical models and visualization tools that are applicable to disease control and prevention especially as related to cancer and cancer patients. This FOA utilizes the NIH Small Grant Program (R03) award mechanism. Period of Support Up to 2 years Funds/Direct Costs $50,000 direct costs per year Program Contact Li Zhu, PhD (301) 594-6546 [email protected] Multiple Institutes, including the National Cancer Institute Mentored Clinical Scientist Research Career Development Award (Parent K08) PA-14-046 Deadline: June 12, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-14-046.html" About The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and “protected time” to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. The NCI K08 award provides support and “protected time” to non-tenured clinician-scientists interested in mentored basic and/or translational cancer research. Candidates must have a clinical degree and practice clinically. This FOA utilizes the NIH (K08) Clinical Investigator Award (CIA) funding mechanism. Period of Support 5 years Funds/Direct Costs $100,000 salary support plus fringe bennefits per year and $30,000 research support per year Program Contact Sonia B. Jakowlew (240) 276-5630 [email protected] SCCC Research Administration Multiple Institutes, including the National Cancer Institute Midcareer Investigator Award in Patient-Oriented Research (Parent K24) PA-14-047 Deadline: June 12, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-14-047.html" About The NCI K24 award provides support and “protected time” to Associate Professor level clinician-scientists to expand their patient-oriented cancer research and to mentor junior clinician-scientists. The applicant must be the Principal Investigator (PI) of an R01, or R01-like, peer-reviewed cancer-focused research grant at the time of application. This research grant must be active for at least two remaining years at the time of K24 application. The PI is expected to maintain such research grant support during the project period. This FOA utilizes the NIH (K24) Midcareer Investigator Award in Patient-Oriented Research funding mechanism. Period of Support Up to 5 years Funds/Direct Costs Salary support up to the maximum legislative salary cap plus fringe benefits per year for 25-50% effort and research support up to $50,000 per year Program Contact Susan E. Lim (240) 276-5630 [email protected] Multiple Institutes, including the National Cancer Institute Mentored Quantitative Research Development Award (Parent K25) PA-14-048 Deadline: June 12, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-14-048.html" About The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and “protected time” for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. The NCI K25 is aimed at fostering the research careers of scientists in quantitative disciplines who are committed to developing research programs in understanding human biology and human disease as it relates to the etiology, pathogenesis, prevention, diagnosis, and treatment of cancer. NCI requires that the K25 applicant identify a mentor whose research is cancer relevant. This FOA utilizes the NIH (K25) Mentored Quantitative Research Career Development Award funding April 2014 Funding Newsletter Page 34 of 49 mechanism. Period of Support Up to 5 years Funds/Direct Costs $100,000 salary support plus fringe bennefits per year and $40,000 research support per year Program Contact Sonia B. Jakowlew (240) 276-5630 [email protected] National Cancer Institute Pilot Studies in Pancreatic Cancer (R21) PA-11-297 Deadline: June 16, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PA-11-297.html" About This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to promote innovative research across multiple disciplines for a better understanding of the biology, etiology, detection, prevention, and treatment of pancreatic cancer. This FOA focuses on pilot projects in early and conceptual stages that could provide a basis for more extended research. These studies may involve considerable risk but should have the potential to generate highly innovative findings or technical/methodological improvements that could have a major impact on the field of pancreatic cancer research. This FOA utilizes the Exploratory/Developmental Research Grant (R21) Award mechanism. Period of Support Up to 2 years Funds/Direct Costs $275,000 direct costs for entire period of support, up to $200,000 in direct costs allowed in any single year Program Contact Mukesh Verma, PhD 6130 Executive Boulevard, Room 5140 Bethesda, MD 20892-7328 (301) 594-7344 [email protected] Multiple Institutes, including the National Cancer Institute Research on Ethical Issues in Biomedical, Social, and Behavioral Research (R03) PA-11-181 Deadline: June 16, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-11-181.html" About The purpose of this Funding Opportunity Announcement (FOA) is to support applications that propose to study high priority bioethical challenges and issues associated with the types of biomedical, social and behavioral research supported by the participating NIH Institutes/Centers. The following specific bioethics topics will be given the highest priority for consideration. These are organized into seven categories: 1) ethical considerations of new and emerging SCCC Research Administration technologies; 2) research study design issues; 3) issues associated with therapeutic misconception and the interface between treatment and research; 4) research involving vulnerable populations and urgent situations; 5) research with existing specimens, data, and health information; 6) dissemination and translation of research findings; and 7) oversight of research. The NCI is particularly interested in studies in evaluation and/or mitigation strategies for ethical challenges in cancer genome studies. This FOA will utilize the NIH Small Grant Program (R03) award mechanism. Period of Support Up to 2 years Funds/Direct Costs $50,000 direct costs per year Program Contact Kim Witherspoon (240) 276-6141 [email protected] Multiple Institutes, including the National Cancer Institute Translational Research at the Aging/Cancer Interface (TRACI) (R21) PA-12-135 Deadline: June 16, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-12-135.html" About This Funding Opportunity Announcement (FOA) encourages translational research proposals in the overlapping areas of human aging and cancer, linking basic and clinical research relevant to the care of older cancer patients through both bench-to-bedside and bedside-tobench approaches. Ultimately, information from the research supported by this initiative should improve the health and well-being of elderly patients at risk for, or diagnosed with, cancer and decrease the functional impairment and morbidity associated with cancer in this population. This FOA utilizes the NIH Exploratory/ Developmental (R21) grant mechanism. Period of Support Up to 2 years Funds/Direct Costs $275,000 direct costs for entire period of support, up to $200,000 direct costs allowed in any single year Program Contact Basil Eldadah (301) 496-6761 [email protected] Multiple Institutes, including the National Cancer Institute Spatial Uncertainty: Data, Modeling, and Communication (R21) PA-11-239 Deadline: June 16, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-11-239.html" April 2014 Funding Newsletter Page 35 of 49 About The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research that identifies sources of spatial uncertainty (i.e., inaccuracy or instability of spatial or geographic information) in public health data, incorporates the inaccuracy or instability into statistical methods, and develops novel tools to visualize the nature and consequences of spatial uncertainty. The National Cancer Institute (NCI) is interested in general methodology of spatial statistical models and visualization tools that are applicable to disease control and prevention especially as related to cancer and cancer patients. This FOA utilizes the NIH Exploratory/Developmental Research Grant Award (R21) mechanism. Period of Support Up to 2 years Funds/Direct Costs $275,000 direct costs over entire period of support Program Contact Li Zhu, PhD (301) 594-6546 [email protected] Multiple Institutes, including the National Cancer Institute Dissemination and Implementation Research in Health (R03) PAR-13-056 Deadline: June 16, 2014 "http://grants.nih.gov/grants/guide/pa-files/PAR-13-056.html" About This Funding Opportunity Announcement (FOA) encourages investigators to submit research grant applications that will identify, develop, and refine effective and efficient methods, structures, and strategies to disseminate and implement research-tested health behavior change interventions and evidence-based prevention, early detection, diagnostic, treatment, and quality of life improvement services into public health and clinical practice settings. This FOA utilizes the NIH Small Research Grant (R03) award mechanism. Period of Support Up to 2 years Funds/Direct Costs Budgets for direct costs of up to $50,000 per year and a project duration of up to two years may be requested for a maximum of $100,000 direct costs over a twoyear project period Program Contact David A. Chambers (301) 443-3747 [email protected] National Cancer Institute Identifying Non-coding RNA Targets for Early Detection of Cancer (R21) PA-12-214 Deadline: June 16, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PA-12-214.html" SCCC Research Administration About This Funding Opportunity Announcement (FOA) encourages research projects on non-coding RNAs (ncRNAs) and their targets in preneoplastic lesions and early stage cancers. This FOA also encourages research projects to assess the usefulness of stable microRNAs (miRNAs) and ncRNAs to predict progression to cancer and as biomarkers for early cancer detection and screening. Building on both basic and biomarker research on microRNAs (miRNA), this FOA will further promote research on all classes of ncRNAs and support the translation of stable miRNAs into cancer screening or diagnostic tests. This Funding Opportunity Announcement (FOA) utilizes the NIH Exploratory/Developmental (R21) grant mechanism. Period of Support Up to 2 years Funds/Direct Costs $275,000 direct costs over entire period of support, up to $200,000 direct costs allowed in any single year Program Contact Wendy Wang 6130 Executive Boulevard, Room 3138 Bethesda, MD 20892-7362 (301) 594-7607 [email protected] National Cancer Institute Biomarkers for Early Detection of Hematopoietic Malignancies (R21) PA-12-220 Deadline: June 16, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-12-220.html" About This Funding Opportunity Announcement (FOA) encourages research projects for the development and validation of biomarkers for: a) early detection, prediction of progression, and recurrence of hematopoietic malignancies, especially in high-risk individuals; and, b) for risk assessment of primary and secondary hematopoietic malignancies. This FOA also encourages the development and improvement of specific technologies and methods for quantitative detection of novel biomarkers associated with hematopoietic malignancies. This program utilizes the NIH Exploratory/Developmental (R21) grant mechanism. Period of Support Up to 2 years Funds/Direct Costs $275,000 direct costs for entire period of suppport, up to $200,000 direct costs allowed in any single year Program Contact Lynn Sorbara 6130 Executive Boulevard, Room 3137 Bethesda, MD 20892-7362 (301) 435-0584 [email protected] April 2014 Funding Newsletter Page 36 of 49 Multiple Institutes, including the National Cancer Institute Pilot and Feasibility Clinical Research Studies in Digestive Diseases and Nutrition (R21) PA-12-139 Multiple Institutes, including the National Cancer Institute Exploratory/Developmental Clinical Research Grants in Obesity (R21) PA-12-179 Deadline: June 16, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-12-139.html" Deadline: June 16, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-12-179.html" About This Funding Opportunity Announcement (FOA) encourages pilot and feasibility clinical and epidemiological research studies of new therapies or means of health promotion and prevention of digestive and liver diseases and nutritional disorders associated with digestive and liver diseases. This FOA utilizes the NIH Exploratory/ Developmental (R21) grant mechanism. About This FOA encourages research grant applications from institutions/organizations that propose to conduct exploratory/developmental clinical studies that will accelerate the development of effective interventions for prevention or treatment of overweight or obesity in adults and/or children. Exploratory epidemiological research with a goal of informing translational/clinical research will also be supported within this program. The types of research applications which NCI is interested in supporting include human intervention studies utilizing bioactive components (e.g., tea polyphenols, calcium) or variation in diet composition strategies that evaluate weight change in populations of interest to NCI. Such populations include individuals with a genetic propensity for cancer as well as those with cancer or those at risk for recurrence of cancer. This FOA utilizes the NIH Exploratory/Developmental (R21) grant mechanism. Period of Support Up to 2 years Funds/Direct Costs $275,000 direct costs for entire period of support, up to $200,000 direct costs allowed in any single year Program Contact Maria Agelli, MD, MS, FACPM 6130 Executive Boulevard, Room 3104 Bethesda, MD 20892-7341 (301) 451-3993 [email protected] Multiple Institutes, including the National Cancer Institute Mentored Patient-Oriented Research Career Development Award (Parent K23) PA-14-049 Deadline: June 12, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-14-049.html" About The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. The NCI K23 award provides support and “protected time” to non-tenured clinician-scientists interested in mentored patient-oriented cancer research. Candidates must have a clinical degree and practice clinically. Documentation of active licensure must be included in the application. This FOA utilizes the NIH (K23) Mentored Patient-Oriented Research Career Development Award funding machanism. Period of Support Up to 5 years Funds/Direct Costs $100,000 salary support plus fringe bennefits per year and $30,000 research support per year Program Contact Susan E. Lim (240) 276-5630 [email protected] SCCC Research Administration Period of Support Maximum of 2 years Funds/Direct Costs $275,000 direct costs over entire period of support, with up to $200,000 in direct costs allowed in any single year Program Contact Sharon A. Ross, PhD 6130 Executive Boulevard, Room 3175 Bethesda, MD 20892-7328 (301) 594-7547 [email protected] Multiple Institutes, including the National Cancer Institute Research on Ethical Issues in Biomedical, Social, and Behavioral Research (R21) PA-11-182 Deadline: June 16, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-11-182.html" About The purpose of this Funding Opportunity Announcement (FOA) is to support applications that propose to study high priority bioethical challenges and issues associated with the types of biomedical, social, and behavioral research supported by the participating NIH Institutes/Centers. The following specific bioethics topics will be given the highest priority for consideration. These are organized into seven categories: 1) ethical considerations of new and emerging technologies; 2) research study design issues; 3) issues associated with therapeutic misconception and the interface between treatment and research; 4) research involving vulnerable populations and urgent situations; 5) April 2014 Funding Newsletter Page 37 of 49 research with existing specimens, data, and health information; 6) dissemination and translation of research findings; and 7) oversight of research. The NCI is particularly interested in studies on evaluation and/or mitigation strategies for ethical challenges in cancer genome studies. This FOA utilizes the NIH Exploratory/Developmental Research Grant Award (R21) mechanism. Period of Support Up to 2 years Funds/Direct Costs $275,000 direct costs for entire period of support, up to $200,000 direct costs allowed in any single year Program Contact Shane Woodward (240) 276-6303 [email protected] National Cancer Institute Validation of Molecular Diagnostics to Predict Patient Outcomes Using Specimens from MultiSite Cancer Trials (R21) PA-12-014 Deadline: June 16, 2014 "http://grants1.nih.gov/grants/guide/pa-files/PA-12-014.html" About This Funding Opportunity Announcement (FOA) encourages the submission of applications to validate the clinical utility of new molecular diagnostics for determining prognosis or predicting response to therapy or toxicity for cancer. This program will support pilot research projects to improve clinical decision-making in the care of cancer patients and as such will support studies that use tumor specimens linked to specific treatment and clinical outcome information. This FOA is not appropriate for molecular diagnostics discovery projects. This FOA will utilize the NIH Exploratory/Developmental Grant (R21) mechanism. Period of Support Up to 2 years Funds/Direct Costs $275,000 direct costs for entire period of support, with no more than $200,000 requested in any single year Program Contact Magdalena Thurin, PhD (301) 496-1591 [email protected] Multiple Institutes, including the National Cancer Institute Mechanisms of Alcohol-Associated Cancers (R21) PA-12-147 Deadline: June 16, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-12-147.html" About This Funding Opportunity Announcement invites applications from researchers with broad ranges of expertise to study the mechanisms by which alcohol increases cancer risk. Target sites for alcohol-related carcinogenesis include the oral cavity, pharynx, esophagus, SCCC Research Administration larynx, breast, liver, and colon. A better understanding of the molecular basis by which alcohol increases cancer risk could lead to improved therapeutic approaches and preventative strategies and would provide guidance on safe levels of alcohol consumption. The goal of this program announcement is to stimulate a broad range of research into the mechanisms by which alcohol contributes to carcinogenesis. This FOA utilizes the NIH Research Grant (R21) award mechanism. Period of Support Up to 2 years Funds/Direct Costs $275,000 direct costs for the entire period of support, up to $200,000 direct costs allowed in any single year Program Contact M. Katherine Jung (301) 443-8744 [email protected] NEW Multiple Institutes, including the National Cancer Institute Extended Development, Hardening and Dissemination of Technologies in Biomedical Computing, Informatics and Big Data Science (R01) PA-14-156 Deadline: June 5, 2014 "http://grants.nih.gov/grants/guide/pa-files/PA-14-156.html" About The goal of this program announcement is to support the extended development, maintenance, testing, evaluation, hardening and dissemination of existing biomedical software. The NIH is interested in promoting a broad base of research and development of technologies in biomedical computing, informatics, and Big Data Science that will support rapid progress in areas of scientific opportunity in biomedical research. It is expected that this research and development is conducted in the context of important biomedical and behavioral research problems and that domain researchers are consulted to make sure that the software is relevant to users. As such, applications are intended to develop enabling technologies that could apply to the interests of most NIH Institutes and Centers and range from basic biomedicine and including research to all relevant organ systems and diseases. Major themes of research include collaborative environments; data integration; analysis and modeling methodologies; and novel computer science and statistical approaches. New opportunities are also emerging as large and complex data sets are becoming increasingly available to the research community. The proposed work should apply best practices and proven methods for software design, construction, and implementation to extend the applicability of existing technologies in biomedical computing, informatics and big data science to a broader biomedical research community. This FOA utilizes the NIH (R01) Research Project award mechanism. April 2014 Funding Newsletter Page 38 of 49 Period of Support 5 years Funds/Direct Costs Application budgets are not limited but need to reflect the actual needs of the proposed project Program Contact NIH Grant Resources (301) 435-0714 [email protected] National Cancer Institute Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (U01) PAR-14-067 Deadline: June 10, 2014 "http://grants.nih.gov/grants/guide/pa-files/PAR-14-067.html" About National Cancer Institute (NCI) invites applications for projects to generate fundamental knowledge of affective processes. Basic affective science projects should have key downstream consequences for single (e.g., genetic testing consent) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum. The FOA is expected to encourage scientific disciplines that have not traditionally conducted cancer research such as affective and cognitive neuroscience, decision science, and consumer science to elucidate perplexing and understudied problems in basic affective and decision sciences with promise of having downstream implications for cancer prevention and control science. This program utilizes the NIH (U01) Research Project Cooperative Agreements award mechanism. Period of Support Up to 5 years Funds/Direct Costs Up to $450,000 direct costs per year Program Contact Rebecca A. Ferrer (240) 276-6914 [email protected] National Cancer Institute NCI Mentored Research Scientist Development Award to Promote Diversity (K01) PAR-12-050 Deadline: June 12, 2014 "http://grants.nih.gov/grants/guide/pa-files/PAR-12-050.html" About The purpose of this award is to provide support and “protected time” (three, four, or five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Awards are not renewable and they are not transferable from one principal investigator (PI) to another. Applications are invited from individuals representative of groups that have been shown to be underrepresented in health-related science, who have been recipients of an NIH Research Supplement to Promote Diversity Award, any Ruth L. Kirschstein National Research Service Award (individual F31/F32 or institutional T32), or can demonstrate that they have been supported in a SCCC Research Administration mentored capacity within any research grant equivalent to an NIH peer-reviewed research grant (e.g., American Cancer Society [ACS] research grant). The overarching goal of this Funding Opportunity Announcement (FOA) is to diversify and expand the pool of independent and talented cancer research investigators. This FOA utilizes the NIH Mentored Research Scientist Development Award (K01) mechanism. Period of Support Up to 5 years Funds/Direct Costs Up to $100,000 per year toward salary and $30,000 per year toward research development costs Budgetary Notes 8% indirect costs are allowed Program Contact John Ojeifo (240) 276-6186 [email protected] National Cancer Institute NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08) PAR-12-051 Deadline: June 12, 2014 "http://grants.nih.gov/grants/guide/pa-files/PAR-12-051.html" About The primary purpose of this program is to prepare individuals for careers that have a significant impact on the health-related research needs of the nation. This program represents the continuation of a long-standing NIH program that provides support and protected time to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This NCI-sponsored K08 award is specifically designed to promote career development of clinical scientists from diverse backgrounds that have been shown to be underrepresented in health-related science and for those who are committed to a career in basic biomedical, behavioral or translational cancer research, including research on cancer health disparities. This FOA utilizes the NIH Research Career Development (K08) grant mechanism. Period of Support Up to 5 years Funds/Direct Costs Up to $100,000 per year toward salary plus benefits and up to $30,000 toward research development costs Program Contact John Ojeifo (240) 276-6186 [email protected] Request for Applications (RFA) April 2014 Funding Newsletter Page 39 of 49 National Cancer Institute Research Answers to NCI's Provocative Questions - Group C (R21) RFA-CA-13-021 FOA are expected to generate findings and data that are directly relevant to inform the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. This FOA will utilize the NIH Research Grants (R21) award mechanism. Deadline: June 20, 2014 "http://grants1.nih.gov/grants/guide/rfa-files/RFA-CA-13021.html" Period of Support Up to 2 years Funds/Direct Costs $275,000 direct costs for an entire period of support Budgetary Notes No more than $200,000 may be requested in any single year Program Contact Stephanie Land (240) 276-6946 [email protected] About The National Cancer Institute (NCI) innovative research projects are designed to solve specific problems and paradoxes in cancer research identified by the NCI Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention. Some of these "Provocative Questions" (PQs) stem from intriguing but older, neglected observations that have never been adequately explored. Other PQs are built on more recent findings that are perplexing or paradoxical, revealing important gaps in current knowledge. Finally, some PQs reflect problems that traditionally have been thought to be intractable but that now may be open to investigations using new strategies and recent technical advances. Each research project proposed in response to this FOA must be focused on solving one particular research problem defined by one specific PQ selected from the list of Provocative Questions. This FOA will utilize the NIH Exploratory/Developmental (R21) award mechanism. Period of Support 2 years Funds/Direct Costs $275,000 direct costs over entire period of support No more than $200,000 in direct costs Budgetary Notes are allowed in any single year Program Contact Emily J. Greenspan (301) 496-1045 [email protected] Multiple Institutes, including the National Cancer Institute Tobacco Control Regulatory Research (R21) RFA-OD-13-010 Deadline: June 17, 2014 "http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-13010.html" About The purpose of this Funding Opportunity Announcement (FOA) is to encourage biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31. Research results from this SCCC Research Administration National Cancer Institute Research Answers to NCI's Provocative Questions- Group E (R01) RFA-CA-13-024 Deadline: June 20, 2014 "http://grants1.nih.gov/grants/guide/rfa-files/RFA-CA-13024.html" About The National Cancer Institute (NCI) innovative research projects are designed to solve specific problems and paradoxes in cancer research identified by the NCI Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention. Some of these "Provocative Questions" (PQs) stem from intriguing but older, neglected observations that have never been adequately explored. Other PQs are built on more recent findings that are perplexing or paradoxical, revealing important gaps in current knowledge. Finally, some PQs reflect problems that traditionally have been thought to be intractable but that now may be open to investigations using new strategies and recent technical advances. Each research project proposed in response to this FOA must be focused on solving one particular research problem defined by one specific PQ selected from the list of Provocative Questions. This FOA will use the NIH Research Project (R01) award mechanism. Period of Support Up to 4 years Funds/Direct Costs Application budgets are not limited, but need to reflect the actual needs of the proposed project Program Contact Emily J. Greenspan (301) 496-1045 [email protected] April 2014 Funding Newsletter Page 40 of 49 National Cancer Institute Research Answers to NCI's Provocative Questions- Group D (R21) RFA-CA-13-023 Deadline: June 20, 2014 "http://grants1.nih.gov/grants/guide/rfa-files/RFA-CA-13023.html" About The National Cancer Institute (NCI) innovative research projects are designed to solve specific problems and paradoxes in cancer research identified by the NCI Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention. Some of these "Provocative Questions" (PQs) stem from intriguing but older, neglected observations that have never been adequately explored. Other PQs are built on more recent findings that are perplexing or paradoxical, revealing important gaps in current knowledge. Finally, some PQs reflect problems that traditionally have been thought to be intractable but that now may be open to investigations using new strategies and recent technical advances. Each research project proposed in response to this FOA must be focused on solving one particular research problem defined by one specific PQ selected from the list of Provocative Questions. This FOA will use the NIH NIH Exploratory/ Developmental (R21) award mechanism. Period of Support 2 years Funds/Direct Costs $275,000 direct costs over entire period of support No more than $200,000 in direct costs Budgetary Notes allowed in any single year Program Contact Emily J. Greenspan (301) 496-1045 [email protected] National Cancer Institute Research Answers to NCI's Provocative Questions- Group D (R01) RFA-CA-13-022 Deadline: June 20, 2014 "http://grants1.nih.gov/grants/guide/rfa-files/RFA-CA-13022.html" About The National Cancer Institute (NCI) innovative research projects are designed to solve specific problems and paradoxes in cancer research identified by the NCI Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention. Some of these SCCC Research Administration "Provocative Questions" (PQs) stem from intriguing but older, neglected observations that have never been adequately explored. Other PQs are built on more recent findings that are perplexing or paradoxical, revealing important gaps in current knowledge. Finally, some PQs reflect problems that traditionally have been thought to be intractable but that now may be open to investigations using new strategies and recent technical advances. Each research project proposed in response to this FOA must be focused on solving one particular research problem defined by one specific PQ selected from the list of Provocative Questions. This FOA will use the NIH Research Project (R01) award mechanism. Period of Support Up to 4 years Funds/Direct Costs Application budgets are not limited, but need to reflect the actual needs of the proposed project Program Contact Emily J. Greenspan (301) 496-1045 [email protected] National Cancer Institute Research Answers to NCI's Provocative Questions- Group E (R21) RFA-CA-13-025 Deadline: June 20, 2014 "http://grants1.nih.gov/grants/guide/rfa-files/RFA-CA-13025.html" About The National Cancer Institute (NCI) innovative research projects are designed to solve specific problems and paradoxes in cancer research identified by the NCI Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention. Some of these "Provocative Questions" (PQs) stem from intriguing but older, neglected observations that have never been adequately explored. Other PQs are built on more recent findings that are perplexing or paradoxical, revealing important gaps in current knowledge. Finally, some PQs reflect problems that traditionally have been thought to be intractable but that now may be open to investigations using new strategies and recent technical advances. Each research project proposed in response to this FOA must be focused on solving one particular research problem defined by one specific PQ selected from the list of Provocative Questions. This FOA will use the NIH Exploratory/ Developmental (R21) award mechanism. April 2014 Funding Newsletter Page 41 of 49 Period of Support 2 years Funds/Direct Costs $275,000 direct costs over entire period of support Budgetary Notes No more than $200,000 in direct costs allowed in any single year Program Contact Emily J. Greenspan (301) 496-1045 [email protected] National Cancer Institute Research Answers to NCI's Provocative Questions - Group C (R01) RFA-CA-13-020 Deadline: June 20, 2014 "http://grants1.nih.gov/grants/guide/rfa-files/RFA-CA-13020.html" About The National Cancer Institute (NCI) innovative research projects are designed to solve specific problems and paradoxes in cancer research identified by the NCI Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention. Some of these "Provocative Questions" (PQs) stem from intriguing but older, neglected observations that have never been adequately explored. Other PQs are built on more recent findings that are perplexing or paradoxical, revealing important gaps in current knowledge. Finally, some PQs reflect problems that traditionally have been thought to be intractable but that now may be open to investigations using new strategies and recent technical advances. Each research project proposed in response to this FOA must be focused on solving one particular research problem defined by one specific PQ selected from the list of Provocative Questions. This FOA will utilize the NIH Research Project (R01) award mechanism. Period of Support Up to 4 years Funds/Direct Costs Application budgets are not limited, but need to reflect the actual needs of the proposed project Program Contact Emily J. Greenspan (301) 496-1045 [email protected] National Cancer Institute Research Answers to NCI's Provocative Questions- Group B (R21) RFA-CA-13-019 Deadline: June 20, 2014 "http://grants1.nih.gov/grants/guide/rfa-files/RFA-CA-13019.html" SCCC Research Administration About The National Cancer Institute (NCI) innovative research projects are designed to solve specific problems and paradoxes in cancer research identified by the NCI Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention. Some of these "Provocative Questions" (PQs) stem from intriguing but older, neglected observations that have never been adequately explored. Other PQs are built on more recent findings that are perplexing or paradoxical, revealing important gaps in current knowledge. Finally, some PQs reflect problems that traditionally have been thought to be intractable but that now may be open to investigations using new strategies and recent technical advances. Each research project proposed in response to this FOA must be focused on solving one particular research problem defined by one specific PQ selected from the list of Provocative Questions. This FOA will utilize the NIH Exploratory/ Developmental (R21) award mechanism. Period of Support Up to 2 years Funds/Direct Costs $275,000 direct costs over entire period of support Budgetary Notes No more than $200,000 in direct costs are allowed in any single year Program Contact Emily J. Greenspan (301) 496-1045 [email protected] National Cancer Institute Research Answers to NCI’s Provocative Questions- Group B (R01) RFA-CA-13-018 Deadline: June 20, 2014 "http://grants1.nih.gov/grants/guide/rfa-files/RFA-CA-13018.html" About The National Cancer Institute (NCI) innovative research projects are designed to solve specific problems and paradoxes in cancer research identified by the NCI Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention. Some of these "Provocative Questions" (PQs) stem from intriguing but older, neglected observations that have never been adequately explored. Other PQs are built on more recent findings that are perplexing or paradoxical, revealing important gaps in current knowledge. Finally, some PQs reflect problems that traditionally have been thought to be intractable but that now may be open to investigations using new strategies and recent technical advances. Each April 2014 Funding Newsletter Page 42 of 49 research project proposed in response to this FOA must be focused on solving one particular research problem defined by one specific PQ selected from the list of Provocative Questions. This FOA will utilize the NIH Research Project (R01) award mechanism. National Cancer Institute Research Answers to NCI's Provocative Questions - Group A (R01) RFA-CA-13-016 Period of Support Up to 4 years Funds/Direct Costs Application budgets are not limited, but need to reflect the actual needs of the proposed project Program Contact Emily J. Greenspan (301) 496-1045 [email protected] Deadline: June 20, 2014 "http://grants1.nih.gov/grants/guide/rfa-files/RFA-CA-13016.html" National Cancer Institute Research Answers to NCI's Provocative Questions - Group A (R21) RFA-CA-13-017 Deadline: June 20, 2014 "http://grants1.nih.gov/grants/guide/rfa-files/RFA-CA-13017.html" About The National Cancer Institute (NCI) invites innovative research projects designed to solve specific problems and paradoxes in cancer research identified by the NCI Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention. Some of these "Provocative Questions" (PQs) stem from intriguing but older, neglected observations that have never been adequately explored. Other PQs are built on more recent findings that are perplexing or paradoxical, revealing important gaps in current knowledge. Finally, some PQs reflect problems that traditionally have been thought to be intractable but that now may be open to investigations using new strategies and recent technical advances. Each research project proposed in response to this FOA must be focused on solving one particular research problem defined by one specific PQ selected from the list of Provocative Questions. This FOA will utilize the NIH Exploratory/Developmental (R21) grant mechanism. Period of Support 2 years Funds/Direct Costs $275,000 direct costs over entire period of support Budgetary Notes No more than $200,000 in direct costs allowed in any single year Program Contact Emily J. Greenspan (301) 496-1045 [email protected] SCCC Research Administration About The National Cancer Institute (NCI) invites innovative research projects designed to solve specific problems and paradoxes in cancer research identified by the NCI Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention. Some of these "Provocative Questions" (PQs) stem from intriguing but older, neglected observations that have never been adequately explored. Other PQs are built on more recent findings that are perplexing or paradoxical, revealing important gaps in current knowledge. Finally, some PQs reflect problems that traditionally have been thought to be intractable but that now may be open to investigations using new strategies and recent technical advances. Each research project proposed in response to this FOA must be focused on solving one particular research problem defined by one specific PQ selected from the list of Provocative Questions. This FOA utilizes the NIH Research Grants (R01) award mechanism. Period of Support Up to 4 years Funds/Direct Costs Application budgets are not limited, but need to reflect the actual needs of the proposed project Program Contact Emily J. Greenspan (301) 496-1045 [email protected] Multiple Institutes, including the National Cancer Institute Tobacco Control Regulatory Research (R01) RFA-OD-13-011 Deadline: June 17, 2014 "http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-13011.html" About The purpose of this Funding Opportunity Announcement (FOA) is to encourage biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31. Research results from this FOA are expected to generate findings and data that are April 2014 Funding Newsletter Page 43 of 49 directly relevant to inform the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. This FOA will utilize the NIH Research Grants (R01) award mechanism. Period of Support Up to 5 years Funds/Direct Costs $499,999 direct costs per year Program Contact Stephanie Land (240) 276-6946 [email protected] National Cancer Institute Early-Stage Innovative Molecular Analysis Technology Development for Cancer Research (R21) RFA-CA-14-003 Deadline: May 20, 2014 "http://grants1.nih.gov/grants/guide/rfa-files/RFA-CA-14003.html" About This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the inception and development of early stage, highly innovative, technologies for the molecular or cellular analysis of cancer. Emerging technologies with significant transformative potential that have not yet been explored in a cancer-relevant use may also be considered. An emerging technology is defined (for the purpose of this FOA) as one that has passed the initial developmental stage, but has not yet been evaluated within the context of cancer-relevant use intended in the application and requires significant modification for the proposed application to establish feasibility. The emphasis of this FOA is on molecular analysis technologies with a high degree of technical innovation with the potential to significantly affect and transform investigations exploring the molecular and cellular bases of cancer. If successful, these technologies would accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be based on molecular and/or cellular characterizations of cancer. This FOA utilizes the NIH (R21) award mechanism for exploratory/developmental pilot projects. Period of Support 3 years Funds/Direct Costs $5000,000 direct costs over entire period of support Budgetary Notes No more than $200,000 in direct costs allowed in any single year Program Contact Tony Dickherber (301) 547-9980 [email protected] SCCC Research Administration National Cancer Institute Validation and Advanced Development of Emerging Molecular Analysis Technologies for Cancer Research (R33) RFA-CA-14-004 Deadline: May 20, 2014 "http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-14004.html" About This Funding Opportunity Announcement (FOA) solicits grant applications proposing research projects on the advanced development of emerging molecular and cellular analysis technologies and technical/analytical validation in an appropriate cancer-relevant biological system. An emerging technology is defined as one that has passed the pilot developmental stage and shows promise, but has not yet been significantly evaluated within the context of its intended use. If successful, these technologies would accelerate research in cancer biology, cancer treatment and diagnosis, early detection and screening, cancer control and epidemiology, and/or cancer health disparities. This FOA solicits projects where proof-of-principle of the proposed technology or methodology has been established and supportive preliminary data are available. Projects proposed to this FOA should reflect the potential to produce a molecular analysis technology with a major impact in a broad area of cancer-relevant research. Projects proposing to use established technologies where the novelty resides in the biological or clinical question being pursued are not appropriate for this solicitation and will not be reviewed. This FOA utilizes the NIH (R33) Exploratory/Developmental Research Grant award mechanism. Period of Support 3 years Funds/Direct Costs $300,000 direct costs per year Program Contact Tony Dickherber (301) 547-9980 [email protected] National Cancer Institute Early-Stage Development of Innovative Technologies for Biospecimen Science (R21) RFA-CA-14-005 Deadline: May 20, 2014 "http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-14005.html" About This Funding Opportunity Announcement (FOA) solicits grant applications proposing technically innovative feasibility studies focused on early-stage development of technologies that address issues related to pre-analytical variations in the collection, processing, handling, and storage of cancer-relevant biospecimens or their derivatives. The overall goal is to develop technologies capable of interrogating and/or maximizing the quality and utility of biospecimens or samples derived from those biospecimens for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to assess sample quality, April 2014 Funding Newsletter Page 44 of 49 preserve/protect sample integrity, and establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to potentially accelerate and/or enhance research in cancer biology, early detection, screening, clinical diagnosis, treatment, epidemiology, and cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. All projects must include quantitative milestones (i.e., technical metrics that determine whether the specific aims have been accomplished). This FOA utilizes the NIH (R21) Exploratory/Developmental Research Grant award mechanism. Period of Support 3 years Funds/Direct Costs $300,000 direct costs per year Program Contact Tony Dickherber (301) 547-9980 [email protected] Period of Support 3 years Funds/Direct Costs $500,000 direct costs over entire period of support Budgetary Notes No more than $200,000 in direct costs allowed in any single year Program Contact Tony Dickherber (301) 547-9980 [email protected] Deadline: June 17, 2014 "http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-13012.html" National Cancer Institute Validation and Advanced Development of Emerging Technologies for Biospecimen Science (R33) RFA-CA-14-006 Deadline: May 20, 2014 "http://grants1.nih.gov/grants/guide/rfa-files/RFA-CA-14006.html" About This Funding Opportunity Announcement (FOA) solicits grant applications proposing technically innovative feasibility studies focused on the advanced development and validation of cancer-relevant technologies that address issues related to pre-analytical variations in the collection, processing, handling, and storage of biospecimens or their derivatives. The overall goal is to develop technologies capable of interrogating and/or maximizing the quality and utility of biospecimens or their derived samples for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to assess sample quality, preserve/protect sample integrity, and establish verification criteria for quality assessment/quality control and handling under diverse conditions. This FOA solicits R33 applications for projects where proof-of-principle of the proposed technology or methodology has already been established and supportive preliminary data are available. Projects proposing to use established technologies where the novelty resides in the biological or clinical question being pursued are an example of a topic not appropriate for this solicitation and will not be reviewed. This FOA utilizes the NIH (R33) Exploratory/Developmental Research Grant award mechanism. SCCC Research Administration Multiple Institutes, including the National Cancer Institute Tobacco Control Regulatory Research (R03) RFA-OD-13-012 About The purpose of this Funding Opportunity Announcement (FOA) is to encourage biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31. Research results from this FOA are expected to generate findings and data that are directly relevant to inform the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. This FOA will utilize the NIH Research Grants (R03) award mechanism. Period of Support Up to 2 years Funds/Direct Costs $50,000 direct costs per year Program Contact Stephanie Land (240) 276-6946 [email protected] April 2014 Funding Newsletter Page 45 of 49 Deadline: Applications accepted on an ongoing basis "http://www.genzyme.com/Responsibility/Grants-andGiving/Applying-for-a-Grant.aspx" About The research funding process for Accelerate Brain Cancer Cure (ABC2) is designed to move the best ideas into the clinic as soon as possible. The sponsor believes that innovation and solid research should not linger in research labs. Proposals need to identify a clear problem and lay out a clear roadmap to find a solution. Since speed counts, rather than simply issuing a yearly request for proposals (RFP), the sponsor constantly scouts research labs for advances which can be translated into new treatments for patients. ABC2 funds projects at each stage of the therapeutic development pipeline to ensure promising leads are advanced as quickly as possible. About In alignment with Genzyme's commitment to innovation in science and areas of unmet medical need, Genzyme supports grants and charitable donations in the following areas: Rare genetic diseases; Thyroid Cancer; Cardiovascular; and Multiple Sclerosis. Not specified Period of Support Funds/Direct Costs Not specified Program Contact David Sandak (202) 419-3140 [email protected] MULTIPLE DATES / OTHER DEADLINES Foundation and Other Sources Genzyme Genzyme Corporation Grants Unspecified Period of Support Funds/Direct Costs Unspecified Program Contact Genzyme (877) GENZYME x14040 Solving Kids' Cancer Clinical Project Grant Awards Deadline: Letters of Intent accepted on an ongoing basis "http://solvingkidscancer.org/work/grants" Solving Kids Cancer (SKC) Therapeutic Development Initiative (TDI) Deadline: Proposals are accepted on an ongoing basis "http://solvingkidscancer.org/work/grants" About The Therapeutic Development Initiative(TDI) is Solving Kids Cancer's strategic program to support the investigation of novel treatments through clinical studies to answer important research questions as quickly, effectively, and economically as possible. The TDI supports clinical testing of promising therapies that may significantly and fundamentally improve treatment for children with pediatric cancer. While SKC values pre-clinical research, only clinical studies are supported via the TDI program. Final pre-clinical work that is requisite to the submission of a protocol may be considered in certain circumstances. The clinical study must focus on neuroblastoma, pediatric central nervous system tumors and/or sarcomas. Period of Support Funds/Direct Costs Budgetary Notes Program Contact 2 years Up to $600,000 direct costs for entire period of support Indirect costs are not allowed Solving Kids Cancer (212) 588-6624 [email protected] Accelerate Brain Cancer Cure Research Grants Deadline: Proposals accepted on an ongoing basis "http://www.abc2.org/smarter-research/how-we-fund" SCCC Research Administration About The spirit of this request is to inspire the scientific research community to submit their best ideas for therapeutic development to improve survivorship for children with neuroblastoma, pediatric central nervous system tumors and sarcomas. The sponsor seeks testable questions and ideas about therapies for these childhood cancers that may provide therapeutic solutions where currently there are none. The sponsor's goal is to fund “dream” ideas that are not currently being funded through existing sources. Period of Support Funds/Direct Costs Budgetary Notes Program Contact Up to 2 years $25,000 to $300,000 direct costs over entire period of support, depending on the nature of the proposed project No indirect costs are allowed Solving Kids' Cancer (212) 588-6624 [email protected] International Waldenstrom's Macroglobulinemia Foundation Research Grant Program Deadline: Applications accepted on an ongoing basis "http://www.iwmf.com/research/applying-for-a-grant.aspx" About The International Waldenstrom's Macroglobulinemia Foundation (IWMF) Research Grant Program offers support for basic scientific research that will further knowledge of the cause, diagnosis, treatment and cure for the disease Waldenstrom's macroglobulinemia. April 2014 Funding Newsletter Page 46 of 49 Period of Support Funds/Direct Costs Program Contact Up to 2 years Up to $200,000 over entire period of support Guy Sherwood (941) 927-4963 [email protected] Period of Support Funds/Direct Costs Budgetary Notes Program Contact General Motors Foundation Research Grants Up to 2 years Not specified Grants are not intended to support the salary of the investigator and indirect costs are not allowed Liddy Shriver Sarcoma Initiative (914) 762-3251 [email protected] Deadline: Applications accepted on an ongoing basis "http://www.gm.com/company/aboutGM/gm_foundation.html " Pediatric Low Grade Astrocytoma (PLGA) Foundation Brain Tumor Research Grants About The General Motors Foundation (GMF) supports organizations working to further research related to the causes, prevention, and treatment of various diseases such as cancer, heart disease, and diabetes. Primary consideration is given to requests that meet the following criteria: • Exhibit a clear purpose and defined need in one of GMF's areas of support • Recognize innovative approaches in addressing the defined need • Demonstrate an efficient organization and detail the organization’s ability to follow through on their proposal Deadline: Letters of Intent accepted on an ongoing basis "http://akidsbraintumorcure.org/medical-research-onchildhood-brain-tumors/apply-for-a-plga-sponsored-grant/" Up to 1 year Period of Support Funds/Direct Costs Not specified Indirect costs are not allowed Budgetary Notes Program Contact General Motors Foundation [email protected] Liddy Shriver Sarcoma Initiative Research Grants Program Deadline: Applications accepted on an ongoing basis "http://sarcomahelp.org/sarcoma-research.html?tpm=2_3" About The sponsor funds basic research seed grants in sarcoma. The sponsor is interested in a wide range of research. Some examples are: understanding the molecular biology of sarcomas; exploring "molecular targets" for new sarcoma therapies; studying chromosomal translocations, the oncogenes they generate and their role in sarcoma development; translational studies; studying vaccines, monoclonal antibodies, and mTOR inhibitors; studying the use of nanotechnology in the diagnosis and treatment of sarcomas; understanding the basis of radiation-induced sarcoma; modeling of the process of metastases; exploring the differences in the development of sarcomas in children, adolescents, young adults and adults; and research directed at the early detection and diagnosis of sarcoma. Grants can be used for the development of models, conducting experiments, development of sarcoma tissue registries, and similar activities involved in support of research into the causes, origins, development, molecular biology, diagnosis, and treatment of sarcoma. The sponsor does not fund clinical trials. SCCC Research Administration About The number one priority of the Pediatric Low Grade Astrocytoma (PLGA) Foundation is to act as a catalyst for researchers world-wide to turn their attention to the area of PLGA brain tumors and to award research grants for the most promising programs and studies which will lead to a better understanding of the causes of PLGA as well as the creation of more effective treatments and a cure for pediatric low grade (grades 1 and 2) astrocytoma tumors. Proposals related to basic and translational projects that can advance understanding of the underlying biology of the development and treatment of PLGA tumors will be considered. Investigators in the early years of their careers are encouraged to apply. Up to 3 years Period of Support Funds/Direct Costs Unspecified Program Contact Pediatric Low Grade Astrocytoma Foundation (PLGA) (914) 762-3494 [email protected] Fanconi Anemia Research Fund, Inc. Head and Neck Carcinogenesis Grant Deadline: Applications accepted on an ongoing basis "http://www.fanconi.org/index.php/research/grant_applicatio ns" About This funding opportunity supports work focused on the molecular pathogenesis, diagnosis, and treatment of head and neck squamous cell carcinoma in patients with Fanconi anemia (FA). The sponsor will consider the following in making funding decisions: responsiveness of the application to the problem of head and neck cancer in Fanconi anemia patients; scientific merit of the proposed project as determined by peer review: the degree to which the results might advance the field, the degree to which the results might improve disease control, the degree to which the results might improve the health and well-being of FA patients; and availability of funds. April 2014 Funding Newsletter Page 47 of 49 Not specified Period of Support Funds/Direct Costs Not specified Program Contact Fanconi Anemia Research Fund, Inc. 1801 Willamette Street, Suite 200 Eugene, OR 97401 (541) 687-4658 [email protected] Intramural Funding Opportunities UM/Scientific Awards Committee Interdisciplinary Team Science (ITS) Pilot Program Grants Deadline: Applications accepted on an ongoing basis "http://uresearch.miami.edu/default.asp?p=265" About Provide up to $50,000 - a maximum of $75,000 in direct research costs to provide resources to assist faculty members in developing new research projects with an emphasis on interdisciplinary science, according to the following criteria: 1) research projects should involve the synergistic collaboration of two or more investigators, ideally from different disciplines or areas of study; 2) research projects should represent new and distinct areas where the applicant research team has no current funding or publications; 3) new and/or expanded direction(s) for existing research programs, where such directions are made possible by collaboration. The ultimate goal for the ITS Pilot Program is to facilitate the creation of new project teams who can develop new interdisciplinary research programs and obtain extramural funding for a Team Science Proposal, Program Project and/or Center grants. UM/Scientific Awards Committee Pilot Study Grants Deadline: Applications accepted on an ongoing basis "http://uresearch.miami.edu/?fo_order=publishdate&fo_ordir =asc&fo_page=1&fo_search=1&item=20&p=43&pid=160& m=fundingph&mid=2&fo_desc=&fo_spr=&fo_pl=&fo_dl=&fo _isls=A*" About Pilot Study Grants provide support to assist faculty in jumpstarting new research areas, including new and distinct research areas where the applicant has no existing funding or publications, as well as new direction(s) for existing research programs in which the applicant has past experience but no current funding. All full time faculty at the Miller School of Medicine are eligible. Preference will be given to faculty who have been granted their appointments at least three years before the SAC meeting at which their applications are to be considered. Applications are due on the 18th of each month (July – March). Period of Support Funds/Direct Costs Program Contact Up to 1 year Up to $20,000 in direct research costs Karen Del Rio (305) 243-5370 [email protected] UM/Scientific Awards Committee Bridge Funding Grants Deadline: Applications accepted on an ongoing basis "http://uresearch.miami.edu/?p=43&pid=160&m=fundingph& mid=2&item=21" Funds/Direct Costs Up to $75,000 direct costs Program Contact Karen Del Rio (305) 243-5370 [email protected] About Bridge Funding Grants provide support to assist faculty in maintaining their research program in the event of a funding lapse during the process of applying for additional extramural funding. Applications are due on the 18th of each month (July – March). UM/Scientific Awards Committee Post-A1 Re-Tooling Grants Period of Support Funds/Direct Costs Deadline: Applications accepted on an ongoing basis "http://uresearch.miami.edu/default.asp?p=265" Budgetary Notes About The Post-A1 Re-Tooling Grants assist faculty who are no longer eligible for Bridge funding, but will support them when their NIH Research Grant (R-series) A1 (revised) application is not funded. This transition phase will allow faculty to "re-tool" their specific aims and research plan for a new NIH submission. Applications are due on the 18th of each month (July – March). Period of Support Funds/Direct Costs Program Contact Program Contact Up to 1 year Up to $25,000 in direct research costs Support for faculty salary will not be provided but the percent effort that the PI and other personnel will spend on the project should be stated in the budget and will be considered as matching funds Karen Del Rio (305) 243-5370 [email protected] Up to 1 year Up to $25,000 in direct research costs Karen Del Rio (305) 243-5370 [email protected] SCCC Research Administration April 2014 Funding Newsletter Page 48 of 49 UM/Scientific Awards Committee Emergency Equipment Grants Deadline: Applications accepted on an ongoing basis "http://uresearch.miami.edu/?fo_order=publishdate&fo_ordir =asc&fo_page=1&fo_search=1&item=22&p=43&pid=160& m=fundingph&mid=2&fo_desc=&fo_spr=&fo_pl=&fo_dl=&fo _isls=A*" About Emergency Equipment Grants provide support to replace or repair intensively used equipment that unexpectedly breaks down or to upgrade existing equipment. These grants are not intended to cover routine or anticipated repair, maintenance, or service contracts. All full time faculty at the Miller School of Medicine are eligible. Applications are due on the 18th of each month (July – March). Period of Support Funds/Direct Costs Program Contact Up to 1 year Up to $20,000 in direct research costs Karen Del Rio (305) 243-5370 [email protected] University of Miami Miller School of Medicine Dean's NIH Bridge Program Deadline: Applications accepted on an ongoing basis "http://uresearch.miami.edu/?p=169&s=33#med" About University of Miami Miller School faculty will likely need additional application cycles in order to successfully obtain new NIH awards and competitive renewals. These gaps in funding may put research programs at risk, many of which have taken significant resources and years to build. In order to maintain the continuity of our outstanding research programs, a pool of resources is available to sustain research that is competitive for NIH funding. These funds are available for up to one year while new or renewed support is pursued. Period of Support Funds/Direct Costs Program Contact Up to 1 year Up to 50% of the recommended 1st year Direct Cost budget (excluding faculty salaries) Karen Del Rio (305) 243-5370 [email protected] SCCC Research Administration April 2014 Funding Newsletter Page 49 of 49
